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SUMMARY - ENGLISH  III 
SUMMARY 
Epstein-Barr virus (EBV), a member of the gammaherpesvirus family, infects about 95% of 
the human population worldwide. EBV is associated with several kinds of cancers such as 
Hodgkin’s lymphoma (HL), Burkitt’s lymphoma (BL) and nasopharyngeal carcinoma (NPC). 
Latent membrane protein 1 (LMP1), EBV’s major oncogene, is an integral membrane protein 
composed of a short cytoplasmic N-terminal domain, six transmembrane spanning segments 
(TMs) linked by small loops and a long cytoplasmic C-terminal domain. LMP1 gene,  
BNLF-1, is highly polymorphic and several LMP1 variants were described. One significant 
difference found among LMP1 variants is their ability to activate NF-κB transcription factor. 
We mapped polymorphisms responsible for increased NF-κB activation levels by natural 
LMP1 variants when compared to B95-8 LMP1 prototype. All critical polymorphisms reside 
in LMP1 TMs 4 and 5. We studied the involvement of each pair of TMs for membrane 
association, self aggregation, binding of LMP1’s cellular partners TRAF3 and β-TrCP, as 
well as for NF-κB activation. Moreover, we described a role for LMP1 in the inhibition of 
MAVS-mediated activation of ISRE and IFNβ-promoter activation. In summary, we observed 
that the different TMs pairs as well as the two intracellular loops are not equivalent. Overall, 
the study showed that TMs play key roles in protein-protein interactions and signaling and 
can be considered as essential regulators of LMP1’s activities. 
 
RÉSUMÉ - FRANÇAIS  IV 
RÉSUMÉ 
Le virus d’Epstein-Barr (EBV), un virus de la famille des gammaherpesvirus, infecte plus de 
95% de la population adulte mondiale. EBV est associé à plusieurs types de cancers dont le 
lymphome de Hodgkin, le lymphome de Burkitt et le carcinome nasopharyngé. La protéine 
membranaire de latence 1 (LMP1), l’oncogène principal d’EBV, est une protéine 
membranaire intégrale composée d’une petite extrémité N-terminale cytoplasmique, six 
segments transmembranaires (TMs) lié par de petites boucles et un long domaine C-terminale 
cytoplasmique. Le gène de LMP1, BNLF-1, est très polymorphe et plusieurs variants de la 
protéine LMP1 ont été décrits. Parmi les variants de LMP1 la majeure différence décrite est 
leur capacité à activer le facteur de transcription NF-κB. Nous avons défini des 
polymorphismes permettant aux variants d’avoir une activation accrue de NF-κB comparé au 
prototype B95-8 LMP1. Tous les polymorphismes cruciaux identifiés dans notre étude se 
trouvent dans les TMs 4 et 5 de LMP1. Nous avons étudié l’implication de chaque paire de 
TMs dans l’association à la membrane, l’auto-agrégation, la liaison aux partenaires cellulaires 
de LMP1 TRAF3 et β-TrCP, ainsi que pour NF-κB. De plus, nous avons décrit un nouveau 
rôle pour LMP1 consistant à inhiber l’activation contrôlée par MAVS de ISRE et du 
promoteur d’IFNβ. En résumé, nous avons observé que les différentes paires de TMs, ainsi 
que les deux boucles intracellulaires, ne sont pas équivalents. Dans l’ensemble, notre étude a 
montré que les TMs jouent un rôle clé dans les interactions protéine-protéine et la 
signalisation et qu’ils peuvent être considérés comme des régulateurs essentiels des activités 
de LMP1. 
 
ABBREVIATIONS   V 
ABBREVIATIONS 
aa amino acid 
β-TrCP Beta-transducin repeat-containing protein 
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HIV-HL HL arising in HIV-infected individuals 
HL Hodgkin’s lymphoma 
HPV Human Papilloma Virus 
HTLV Human T-cell Lymphotropic virus 
HHV Human herpes virus 
IARC International Agency for Research on Cancer 
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LMP1 Latent Membrane Protein 1 
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NF-κB Nuclear Factor-kappaB 
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1.1 HUMAN TUMOR VIRUSES 
For the year 2002, 1.9 million of cancers were attributable to infectious agents, such as 
viruses, Helicobacter pylori or parasites, associated with 17.8% of all cancers. Developing 
countries are more affected with respect to cancers attributable to infectious agents. Viruses 
contribute to the major part of human cancer worldwide, 12.1% [1]. The International Agency 
for Research on Cancer (IARC) classified all these agents as group 1 carcinogens (for 
classification see: http://monographs.iarc.fr/ENG/Classification/index.php). Several viruses 
are classified as group 1 carcinogens: Epstein-Barr virus (EBV - HHV-4), Hepatitis B virus 
(HBV), Hepatitis C virus (HCV), Human Immunodeficiency virus type 1 (HIV-1), Human 
papilloma virus (HPV) high risk 16-18-31-33-35-39-45-51-52-56-58-59, Human T-cell 
lymphotropic virus type 1 (HTLV-1) and Kaposi sarcoma-associated herpesvirus (KSHV - 
HHV-8). Other viruses are classified as probably carcinogenic to humans (group 2A): HPV 
68; or possibly carcinogenic to humans (group 2B): HIV-2, HPV low risk 5-8-26-30-34-53-
66-67-69-70-73-82-85-97. In 2008, a new polyomavirus has been found in Merkel cell 
carcinoma by Feng et al. and named Merkel cell polyomavirus (MCPyV) [2]. This virus was 
not yet classified by the IARC, but is in the list of priority agents for future IARC 
monographs [3].  
A major advance in the fight against cancer would be to understand the oncogenic 
mechanisms of viruses in order to develop specific treatments and vaccines [4,5]. The first 
vaccine against a tumor-associated virus was developed in the late 1970s against HBV. More 
recently, in the mid 2000’s, two vaccines against HPV were available on the market: Gardasil 
(MERK) containing HPV genotypes 6, 11, 16 and 18, and Cervarix (GlaxoSmithKline) 
containing genotypes 16 and 18. 
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1.1.1 IARC GROUP 1 CARCINOGENS 
Epstein-Barr virus (EBV) or Human herpes virus 4 (HHV-4) [Herpesviridae family, 
Gammaherpesvirinea subfamily, Lymphocryptovirus genus] is an enveloped double stranded 
DNA virus, which causes infectious mononucleosis and is associated with several tumors in 
humans such as Burkitt’s lymphoma, nasopharyngeal carcinoma, Hodgkin’s lymphoma, B 
and T cell lymphoma, post-transplant lymphoproliferative disease, leiomyosarcomas, gastric 
carcinomas. Patients with immunodeficiency as transplanted or AIDS patients are more 
susceptible to develop EBV-associated cancers. EBV was the first human tumor virus 
described. 
Hepatitis B virus (HBV) [Hepadnaviridae family, Orthohepadnavirus genus] is an enveloped 
double stranded DNA virus, which causes acute and chronic hepatitis. If the infection lasts 
more than 3 months it can lead to cirrhosis or liver failure and to hepatocellular carcinoma.  
Hepatitis C virus (HCV) [Flaviviridae family, Hepacivirus genus] is an enveloped ssRNA(+) 
virus, which causes acute and chronic hepatitis which can result in cirrhosis and 
hepatocellular carcinoma. 
Human imunodeficiency virus type 1 (HIV-1) [Retroviridae family, Orthoretrovirinae 
subfamily, Lentivirus genus] is an enveloped ssRNA(+) virus, which acts mainly through 
immunosuppression to increase the risk of several cancers such as Kaposi sarcoma, non-
Hodgkin lymphoma, cancer of the cervix – these three cancers are “AIDS-defining 
conditions” –, Hodgkin’s lymphoma, anal cancer, seminoma, myeloma, and less certainly, 
cancers of the lip, brain and lung. Even if HIV-1 does not have proper oncogenic properties it 
was classified as group 1 carcinogen by the IARC in 1996. 
Human papilloma virus (HPV) [Papillomaviridae family] is a small non-enveloped double 
stranded DNA virus, which causes benign papillomas or warts in humans by infecting 
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epithelial cells. It causes cervical cancer, genital cancers, skin cancer and cancers of the oral 
cavity and pharynx.  
Human T-cell Leukemia virus type 1 (HTLV-1) [Retroviridae family, Orthoretrovirinae 
subfamily, Deltavirus genus] is a single stranded ssRNA(+) virus, which causes adult T-cell 
leukemia/lymphoma. It has a slow transforming potency and a long latency, but once tumor 
formation begins the progression is rapid 
Kaposi’s sarcoma-associated Virus (KSHV) or Human herpes virus 8 (HHV-8) 
[Herpesvirus family, Gammaherpesvirinea subfamily, Rhadinovirus genus] is a double 
stranded DNA virus. KSHV is a cofactor in the development of Kaposi sarcoma, multicentric 
Castelman’s disease and pleural effusion lymphoma. 
More details about carcinogenic viruses can be found in the following book and reviews 
[1,4,5,6,7]. 
 
1.2 HUMAN GAMMA-HERPESVIRUSES 
Gamma-herpesvirus subfamily includes two genera: the gamma 1 or lymphocryptovirus 
genus to which belongs EBV also named HHV-4 and the gamma 2 or rhadinovirus genus to 
which belongs KSHV also named HHV-8. EBV and KSHV, as all herpesviruses, have a life 
cycle divided into two main phases: a lytic and a latent cycle. In the lytic phase new virions 
are produced in infected cells and viruses can spread in new cells or hosts. In latent phase 
viral genome is kept in host nucleus as an episome and few viral genes are expressed [7,8]. 
Both viruses are activators of the NF-κB pathway, which is involved in the viral life cycle of 
EBV and KSHV and is constitutively active in tumor cells from malignancies associated with 
these viruses. EBV-encoded latent membrane protein 1 (LMP1) and KSHV-encoded viral 
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FLICE (caspases-8)-inhibitory protein (vFLIP) are both able to constitutively activate NF-κB 
canonical and non-canonical pathways. This constitutive activation sustains latent infection 
and favors viral persistence in vivo increasing cell survival and proliferation, and is even 
essential for progression of virus-associated lymphomas [8]. 
 
1.3 EPSTEIN-BARR VIRUS 
EBV was discovered in 1964 by Epstein, Achong and Barr [9] and was the first virus to be 
associated with human cancer [10]. EBV is an enveloped linear double stranded DNA virus 
with a genome of 184 kb [7]. For the structure of EBV virions see Figure 1.  
 
 
Figure 1: Structure of EBV virion EBV is composed of a genomic DNA core in a capsid of 162 
capsomeres, an envelope with external glycoproteins, and a tegument between the capsid and the 
envelope. Taken from: http://expasy.org/viralzone/all_by_species/185.html.  
 
EBV is a highly successful parasite infecting more than 95% of human adult population 
worldwide and is mainly spread by oral route through saliva. Primary infection is generally 
asymptomatic and occurs in oropharyngeal cavity. In developing countries most children are 
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infected before the age of three years and infection is mostly asymptomatic; whereas in 
developed countries primary infection is often delayed. Fifty percent of children are still 
seronegative at the age of 10 years and the acquisition of the virus occurs as adolescent or 
young adult. In that case 25% of the infections lead to infectious mononucleosis (IM) [7]. IM 
is a benign lymphoproliferative disorder, which symptoms are fever, sore throat, enlarged and 
painful lymph glands in the neck, severe and debilitating fatigue, and may last several months 
[11]. Among young males with X-linked lymphoproliferative disease (XLP), EBV infection is 
lethal and they succumb to fulminant IM with an excessive immune response. XLP is due to a 
single mutation in SAP (signaling lymphocytic-activation molecule [SLAM] associated 
protein) that is expressed in T and natural killer cells [11,12,13,14]. EBV is associated with 
malignances: nasopharyngeal carcinomas (NPC), Burkitt’s lymphoma (BL), Hodgkin’s 
lymphoma (HL), B and T/NK cell lymphoma, post transplant lymphoproliferative disorder 
(PTLD), lymphoproliferative disease in immunosuppression, undifferentiated carcinomas of 
nasopharyngeal type, gastric carcinoma. More details about EBV associated diseases can be 
found in these book and reviews [7,11,15]. 
EBV is not cleared after primary infection, but establishes a life-long latent infection in 
human memory B cells as episome or rarely integrates host DNA. Under some circumstances 
the virus is reactivated and lytic cycle occurs with production of new EBV virions [7]. 
EBV can establish three different types of latencies in cells, which are associated with 
different disorders (Table 1). In type III latency EBV expresses the 9 latent proteins: 6 EBV 
nuclear antigens (EBNA1, 2, 3A, 3B, 3C, LP), 3 latent membrane proteins (LMP1, 2A, 2B) 
and two small non-coding RNAs: EBER1 and EBER2 (Figure 2 and Table 1). This type of 
latency is found in lymphoblastoid cell lines (LCLs), infectious mononucleosis, X-linked 
disorder and lymphoproliferative disease in immunosuppression. In type II latency only 
EBNA1, LMP1 and LMP2 are expressed in cells. This type of latency is found in tumor cells 
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from NPC, HL and T/NK cell lymphoma. In type I latency, only EBNA1 and EBER RNAs 
are found. This panel of genes is only expressed in Burkitt’s lymphoma and in some memory 
B cells [7,16,17]. 
Some of these proteins play an essential role: EBNA1 is essential during the cellular division 
by binding the viral DNA to the cellular chromosomes, LMP1 and LMP2 prevent apoptosis of 
EBV infected cells [7].  
 
 
Figure 2: EBV genome and proteins expressed in la tencies. The six EBV nuclear antigens 
(EBNAs), the three latent membrane proteins (LMPs) and the two small non-coding RNAs (EBERs) 
are shown with arrows. Taken from [16]. 
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Table 1: EBV types of latencies and related diseases. 
Latency type EBV proteins expressed Occurrence/disorders 
0 
 
- Memory B cells 
I EBNA1 
LMP2A 
- Burkitt’s lymphoma 
- Memory B cells 
II EBNA1 
LMP1  
LMP2A, 2B 
- Classical Hodgkin lymphoma 
- Nasopharyngeal carcinoma 
- Nasal NK/T-cell lymphoma 
III 
EBNA1,2,3A,3B,3C,-LP 
LMP1 
LMP2A, 2B 
- Lymphoblastoid cell lines 
- Infectious mononucleosis 
- Post-transplant lymphomas 
- AIDS-related lymphomas 
 
Two different types of EBV are described: type 1 EBV based on B95-8 strain and type 2 EBV 
based on AG876 strain. Type 1 and type 2 EBV differ in their nuclear protein genes and 
contain specific polymorphisms in EBNA-2, EBNA-3A, EBNA-3B, and EBNA-3C [18,19]. 
80% to 90% of EBV isolated from Caucasian and Southeast Asian populations are of type 1 
EBV. In African populations type 2 reaches an almost equal prevalence as type 1 EBV. Even 
if type 1 EBV transforms B cells to LCL more efficiently than type 2, no strain specific 
disease association has been observed [7]. Two or more EBV co-resident strains can be 
present in one individual, either of both type 1 and 2 or all of the same type. The question is 
still open whether the different strains are acquired at the same time or serially over time. It 
has been suggested that multiple co-resident strains are mainly found in immunocompromised 
patients, but with determination by heteroduplex tracking assay multiple strains have been 
found in immunocompetent patients too [20,21,22]. 
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1.3.1 EBV AND HIV 
EBV, as KSHV, is an important health problem for HIV infected patients, because of its high 
capacity to cause malignancies. In HIV-infected patients about 75% of non-Hodgkin 
lymphomas and the majority of HL are EBV positive [23,24]. In immunocompetent 
individual EBV reaches equilibrium with the immune system. When a person is infected by 
HIV, the tight equilibrium between EBV and the host immunity breaks. EBV viral load 
increases in HIV infected patients early after HIV seroconversion [25,26]. Primary HIV 
infection increases B-cell stimulation, an environment favorable for proliferating B-cells and 
thus reactivation of EBV leading to a higher EBV viral load [27]. Indeed, EBV viral load is 
high in HIV-infected patients it is not a predictive value for tumor formation, such as in 
transplant recipients [28,29,30,31]. Patients with higher EBV viral load are not those who 
develop cancer and the AIDS progressors are not those with higher EBV viral load, meaning 
that the degree of immunosuppression is not linked with EBV viral load but rather with B cell 
status [26].  
EBV reactivation is not only linked with cancer in HIV-infected patients, but also with hairy 
leukoplakia that is characterized by the appearance of white irregular plaques on the tongue 
due to uncontrolled infection in the oropharynx of patients with severe immunosuppression 
[32]. 
Data from the Swiss HIV Cohort Study (SHCS) and cancer registries in Switzerland estimate 
excess cancer risk in persons infected with HIV and investigate the modifying effects of 
highly active antiviral therapy (HAART) use on cancer risk [33,34]. These analyses revealed 
that persons infected with HIV who are treated with HAART have a lower risk of developing 
Kaposi sarcoma and non-Hodgkin lymphoma than untreated patients; however, the incidence 
risk for Hodgkin lymphoma remains high in patients treated with HAART [33,34]. These 
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results suggest that additional factors than HIV-induced immunosuppression such as genetic 
viral variations are involved in the development of this type of lymphoma. 
 
1.3.2 EBV AND INTERFERON-β  
The host immunity is an efficacious way of defending cells against microbes. Viruses, as 
obligate pathogens, need to infect host cells to replicate and survive [7]. In this way, they 
evolved many different mechanisms to evade the host defenses, one of them the subversion of 
the innate immune response. This first line of defense, which first recognizes the invading 
agents and avoids their spread, leads to the induction of Type I interferon (IFNs) (IFNα/IFNβ) 
[35,36]. The IFNβ is the major player of the Type I interferon and will be the focus of this 
chapter. 
The activation of the IFNβ pathway is a two steps process. During the first step, pathogens are 
sensed by the first defense line of the innate immune system, the pattern-recognition receptors 
(PRRs) among them Toll-like receptors (TLR) or RIG-like receptors (RLR) [37,38]. This 
sensing leads to the activation of the three transcription factors NF-κB, IRF3 and AP-1 (c-
Jun/ATF-2), which translocate to the nucleus, bind to IFNβ-promoter and together induce the 
expression of IFNβ that is secreted [35,38]. During the second step, the secreted IFNβ bind to 
the Interferon-Alpha/Beta receptors (IFNAR) 1 and 2 of the same cell or of the neighboring 
cells to warn them of the danger. Thanks to this alert, cells mount antiviral response by 
inducing the activation of the Jak/STAT pathway leading to the induction of IFN-stimulated 
genes (ISGs). The simultaneous expression of several ISGs induces antiviral state [35,38]. 
Herpesviruses have to evade host immune defense at the infection and replication steps (lytic 
cycle), but also to stay hidden in the host cells during the persistent infection (latent cycle) 
[38,39]. EBV activates the IFN pathway during the first steps of infection [40,41]. This 
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activation is counteracted by the synthesis of de novo viral proteins, which inhibit both IFNα 
and IFNβ [38,39,40,41]. Whereas several strategies of immune escape during lytic infection 
have been identified, how EBV may circumvent the innate immune responses in the context 
of a latent infection is much less understood. During the latent infection, few viral latent 
proteins are expressed, their number differing according to the latency type, as well as small 
non coding nonpolyadenylated RNAs [42]. It has been shown that LMP2A and LMP2B limit 
the IFN signaling by degrading IFNAR 1 and 2 [43] and that LMP1 plays a determinant role 
in the block of Type I IFN by suppressing the phosphorylation of STAT1 and -2 through 
Tyk2 binding [44], but the observations do not fully explain how the virus counteract innate 
immune defenses. 
 
1.4 LATENT MEMBRANE PROTEIN 1  
1.4.1 GENERALITIES 
Latent membrane protein 1 (LMP1), encoded by the BNLF-1 gene, is the major transforming 
protein of EBV. LMP1 is an integral membrane protein composed by a short cytoplasmic  
N-terminal domain of 24 amino acids, 6 markedly hydrophobic transmembrane domains 
linked by short loops (aa 25-186), a long cytoplasmic C-terminal domain of about 200 amino 
acids (Figure 3) [45,46,47]. The gene encoding LMP1 contains two short introns. The  
N-terminal part of the protein is important for the correct insertion of the protein in the plasma 
membrane and is probably the attachment point for ubiquitin. LMP1 has a short half-life of 
two to five hours depending on the cell type [48,49,50] and is degraded via the proteasome 
[51]. The transmembrane segments are involved in self-aggregation and oligomerization of 
the protein. LMP1 localizes in large patches in the plasma membrane [52]. The C-terminal 
part possesses most of the signaling activity, e.g. NF-κB activation, through two C-terminal 
activating regions (CTAR) 1 (aa 351-386) and CTAR2 (aa 351-386) [53]. The two regions 
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have consensus sequences that have docking activities for cellular proteins permitting their 
signaling activities. CTAR1 and CTAR2 are both involved in NF-κB activation, but CTAR2 
at a greater level [53].  
 
Figure 3: Schematic representation of LMP1. EBV-encoded LMP1 is an integral membrane protein 
composed of a short cytoplasmic N-terminal region (aa 1-24), six transmembrane spanning domains 
linked by extra- and intra-cellular loops of 4 to 12 amino acids (aa 25-186) and a long cytoplasmic  
C-terminal region (aa 187-386) containing two major regions for signaling, C-terminal activating 
region 1 (CTAR1) and CTAR2. LMP1 is involved in several signaling pathways and activates both 
NF-κB1 and NF-κB2 pathways. Taken from [42]. 
 
LMP1 acts as a constitutively active tumor necrosis factor receptor (TNFR) mimicking the 
CD40 receptor [54], binds to TRAFs [55] and thereby can engage several pathways, among 
them NF-κB [56,57,58], AP-1 [59], PI3K/Akt [60], c-Jun N terminal kinase (JNK) [10], 
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p38/ATF2 [61] or JAK/STAT [62] (Figure 3). NF-κB activation by LMP1 is critical for EBV-
transformed lymphoblastoid cell survival [63]. Therefore LMP1 is essential for the conversion 
of primary B lymphocytes to lymphoblastoid cell lines (LCL) and protect them from 
apoptosis through the induction of Bcl-2 [64]. LMP1 has oncogenic effects in rodent 
fibroblast cell lines [65] and is able to create tumors in nude mice by inducing phenotypic 
changes in a non-tumorigenic human keratinocyte line [66] and causes lymphoma in 
transgenic mice [67]. 
 
1.4.2 LMP1 VARIANTS 
LMP1 gene, BNLF-1, is highly polymorphic. Multiple EBV strains with different LMP1 
variants are naturally present in the population. Interestingly, LMP1 variants diverge more 
within type 1 EBV than between type 1 and type 2 EBV [68]. 
The first and best characterized LMP1 is B95-8, known as the prototype LMP1, which was 
isolated from a cell line infected by an EBV from an American patient with IM [46,47,69,70]. 
CAO LMP1 isolated from a Chinese NPC is 88% similar to the prototype B95-8 LMP1 and 
differs by 27 amino acids, an insertion of three additional repeats (total of 28 aa) and a 30-bp 
deletion (10 aa: 343GGGHSHDSGH352
71
) in the C-terminal end adjacent to the CTAR2 region. 
CAO has a higher molecular weight than B95-8 due to its protein length, 404 amino acids 
versus 386, respectively [ ]. CAO LMP1 activates NF-κB and AP-1 pathways more potently 
than B95-8, is more strongly expressed upon transfection and more tumorigenic in a nude 
mice model [50,72]. 
AG876 LMP1, type 2 EBV, isolated from an African BL is 93% similar to the prototype and 
contains 12 amino acid changes and the same 30-bp deletion as CAO LMP1 [68]. It induces 
NF-κB at the same level as B95-8 LMP1 [72]. 
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Raji LMP1 isolated from an African BL is 97.5% identical to the prototype and contains 19 aa 
changes [71,73].  
Other LMP1 variants have been studied for their differences in amino acid sequences and 
classified according to these differences. Two different classifications have been proposed by 
Sandvej et al. [74] and Edwards et al. [75].  
Despite the genetic diversity, EBV is a DNA virus that is stable over time. Brousset et al. 
demonstrated that LMP1 amplified from samples of two patients taken at first tumor episode 
and after relapse have the same sequence even after several years [76]. 
 
1.4.3 LMP1 INTERACTION AND SIGNALING 
1.4.3.1 NF-κB 
Nuclear factor-kappaB (NF-κB) comprises a family of eukaryotic inducible transcription 
factors, which are involved in inflammation, stress, immune response and malignant 
transformation. The proteins expressed by this family are conserved from Drosophila 
melanogaster to humans reflecting the importance of the NF-κB pathways [77]. 
In the absence of stimulus, NF-κB is tightly bound to the inhibitor of κB (IκB), which masks 
domains for nuclear localization and DNA binding. The NF-κB/IκB complex is therefore 
sequestered in the cytoplasm of the cell. 
In stimulated cells, two different NF-κB pathways can be activated: the canonical or classical 
one and the noncanonical or alternative one. Canonical NF-κB pathway involves IκB kinase 
(IKK) complex composed of IKKα, IKKβ and IKKγ. IKK mediates the phosphorylation of 
IκB, which permits its ubiquitination by the ubiquitin ligase SCFβ-TrCP, followed by its 
degradation mediated by the 26S proteasome. This allows the release of NF-κB dimer, such as 
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p50-RelA or p50-cRel [77,78,79]. Noncanonical NF-κB pathway involves NF-κB inducing 
kinase (NIK) that in association with IKKα binds the C-terminal part of p100, which is the 
autoinhibitory part of the dimer, allowing its phosphorylation and subsequent recognition and 
ubiquitination by SCFβ-TrCP
77
. This allows its recognition by the 26S proteasome, its proteolysis, 
its processing in p52 and the release of NF-κB dimer, such as p52-RelB. In both pathways 
uncovered dimers are able to enter the nucleus and activate target gene expression. The 
canonical pathway is self-regulated through the activation of the gene encoding IκBα, is 
transient and lasts 30-60 minutes. The duration of the noncanonical NF-κB pathway is longer 
[ ,78,79]. 
NF-κB transcription factors bind to 9-10 base pairs DNA sites called κB sites as dimers  
[77]. They activate more than one hundred genes with key cellular function, e.g. Il-2 or 
Interferon gamma, which are involved in immunity, CD40 which is an immunoreceptor, IκBα 
which is a NF-κB inhibitor, as well as nfkb2 which is the NF-κB p100 precursor [77].  
NF-κB plays a determinant role in cell transformation: tumor promotion is mediated by its 
anti-apoptotic functions and aberrant activation of NF-κB is associated with tumorigenesis 
[80,81]. 
Interestingly, LMP1 activates both NF-κB pathways: the classical mostly through CTAR2 and 
the alternative mostly through CTAR1. 
 
1.4.3.2 β-TrCP 
Beta transducing-repeat containing protein (β-TrCP) is the Fbox subunit of the S-phase-
kinase-associated protein-1 (Skp-1)-Cullin1-Fbox protein (SCF) E3 Ubiquitin ligase [78,82]. 
SCFβ-TrCP recognizes specifically phosphorylated substrates and confers their ubiquitination 
leading to their degradation by the 26S proteasome and plays a critical role in the regulation 
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of cell cycle progression, cell proliferation and survival. Among SCFβ-TrCP
78
 substrates are  
β-catenin, IκB and caspase-3; HIV-1 encoded Vpu is a pseudosubstrate of the β-TrCP 
[ ,82,83]. By controlling the substrate specificity, β-TrCP is a key subunit of the ubiquitin 
ligase complex. Via the N-terminal F-box domain β-TrCP binds to Skp-1 and via the  
C-terminal WD-40 domain to phosphorylated substrates [78]. The majority of β-TrCP 
substrates contain a canonical DSGxxS motif in which the phosphorylation of the two serine 
residues is required to allow recognition [84]. A similar DSG motif is found in the C-terminal 
part of LMP1, within the CTAR1 [82]. β-TrCP2 was shown to bind LMP1 motif [82]. 
β-TrCP is a highly conserved protein from Xenopus to humans. Human β-TrCP is present in 
cells in two homologs: β-TrCP1 (aka FWD1/Fbw1a) and β-TrCP2 (aka HOS/Fbw1b).  
β-TrCP1 was mainly found in the nucleus, whereas β-TrCP2 is predominantly localized in the 
cytoplasm [84]. They are divided in several spliced forms all containing the F-box motif at the 
N-terminus and seven WD40 repeats at the C-terminus [78].  
 
1.4.3.3 TRAF3 
Tumor necrosis factor receptor (TNFR) associated factors (TRAFs) are cytoplasmic adapter 
proteins. Members of the TRAF family share a similar TRAF domain in the C-terminal part 
of the molecule allowing the homo-/hetero-trimerization, interaction with receptor or 
downstream signaling molecules. They contain three other domains: a Zinc binding motif in 
their N-terminal part, a RING finger and an isoleucine zipper [79]. 
TRAFs play vital roles in inflammatory responses, lymphoid tissue development, and 
orchestration of adaptive immune responses via activation of both canonical and noncanonical 
NF-κB signaling pathways [79]. TRAF2, TRAF5 and TRAF6 have a role in activation of  
NF-κB canonical pathway, whereas the role of TRAF3 is much more complex because it has 
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been shown to be a negative regulator of the noncanonical pathway [85]. It was shown that a 
lack of TRAF3 leads to an increase of NIK level implying a constitutive p100 processing and 
so an activation of the noncanonical NF-κB pathway [79]. 
TRAF3 can associate with the CD40 receptor, which is mimicked by EBV LMP1 protein. 
TRAF3 can also bind to the LMP1 upon a PxQxT motif present in CTAR1 [86]. 
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2.1 AIM OF THE CHAPTER 1 
A large part of the population is infected by EBV, but only few people develop EBV-
associated malignancies. Factors contributing to the development of tumors are of 
environmental nature, genetic background of either host or virus. In our study we focus on the 
possible role of LMP1 strain variations in tumor pathogenesis. We were interested to study 
LMP1 because it was shown to be EBV’s major oncogene and expressed in the majority of 
tumor types. The gene encoding LMP1 is polymorphic. CAO, a variant isolated from Chinese 
NPC was found to have increased potential to transform rodent fibroblasts and to induce 
tumors in nude mice [71], leading to the hypothesis that polymorphisms within LMP1 gene 
influence the susceptibility to develop EBV-associated diseases. Moreover, when compared to 
B95-8 LMP1, CAO induces higher levels of NF-κB activation, an effect that has been 
reported in several cell types [50,72]. Despite extensive studies, polymorphisms associated 
with functional differences such as an increased capacity to activate NF-κB have not yet been 
identified. 
 
2.2 AIM OF THE CHAPTER 2 
LMP1, a mimic of CD40 receptor, is an integral membrane protein with a short cytoplasmic 
N-terminus, six transmembrane-spanning segments (TMs) and a 195 amino acids long  
C-terminal domain [45,46,54]. The N- and C-terminal domains of the protein were widely 
analyzed for their role in LMP1 signaling properties [87,88,89]. The TMs were less studied 
and few are known about the relative contribution of each pair of TMs to the functional 
activity [90,91,92,93,94]. To analyze the importance of each TM pairs we used deletion 
mutants with four or two TMs to perform functional analyses. 
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Comments on the manuscript: 
It has been reported that LMP1 is highly polymorphic and several variants have been 
described. Among these LMP1 variants different abilities to activate NF-κB pathways were 
observed. The aim of this study was first to map polymorphisms involved in increased 
activation of NF-κB and then to determine whether these polymorphisms were enriched in 
samples from patients with EBV-associated cancer in a pilot study in the Swiss HIV Cohort 
Study (SHCS). 
We found three polymorphisms determinant for increased NF-κB activity, two of them, linked 
with additional polymorphisms, defined two distinct LMP1 phylogenetic groups: 
I124V/I152L and F144I/D150A/L151I. They are predictors of high NF-κB activation levels, 
and were tested for their role in Hodgkin’s lymphoma etiology. No association was found 
between these predictors of high NF-κB activation levels in vitro and the development of 
Hodgkin’s lymphoma among HIV-infected individuals enrolled in the SHCS. 
 
The data not shown contained in the manuscript are described at the end of the Chapter 1 
under Supplementary figures and methods. The sequences of the LMP1 variants obtained in 
the study are reported in the Appendix 1. 
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ABSTRACT 
Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1), a multifunctional 
oncoprotein, is a powerful activator of the transcription factor NF-κB, a property that is 
essential for EBV-transformed lymphoblastoid cell survival. Previous studies reported LMP1 
sequence variations and induction of higher NF-κB activation levels compared to the 
prototype strain B95-8 LMP1 by some variants. Here we used blood of individuals included 
in the Swiss HIV Cohort Study (SHCS) to analyze LMP1 genetic diversity and LMP1-
mediated NF-κB activation levels by gene reporter assay. We found that a number of variants 
mediate higher NF-κB activation levels when compared to B95-8 LMP1 and mapped several 
polymorphisms responsible for this phenotype, among them F144I and I124V. The sets of 
polymorphisms I124V/I152L and F144I/D150A/L151I were chosen as markers to assess 
whether the presence of LMP1 variants with increased NF-κB activation in vitro influences 
Hodgkin’s lymphoma (HL) susceptibility in a pilot epidemiological study within the SHCS.  
The analysis of LMP1 variants in blood of SHCS participants with or without HL diagnosis 
showed that I124V/I152L and F144I/D150A/L151I, when combined, were present in more 
than 50% of the samples from each group. Concordant with a high distribution in the two 
groups of patients, the two sets of polymorphisms are not identified as predictive factors 
associated with HIV-HL susceptibility when analyzed either together or individually by a 
logistic regression model. In order to determine to which extend EBV strains differ between 
blood and tumor, we further compared LMP1 sequences present in the blood and in the 
corresponding biopsy from HIV-HL. The good correspondence of LMP1 variants between 
blood and tumor biopsies in 10/15 cases indicates that larger future studies using blood 
samples would be relevant to the identification of viral polymorphisms influencing the 
development of EBV-associated malignancies.  
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INTRODUCTION 
Epstein-Barr virus (EBV) infects more than 90% of human adults worldwide. EBV causes 
infectious mononucleosis and is associated with several human malignancies, among them 
nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma and Hodgkin’s lymphoma (HL) [42]. 
EBV infection of B-lymphocytes is mostly non-lytic and results in the expression of a limited 
number of nuclear and membrane proteins. EBV-encoded latent membrane protein 1 (LMP1) 
is a multifunctional oncoprotein essential for EBV-induced B-cell proliferation and 
transformation in vitro [65,95,96,97]. LMP1 also has transforming effects on non-lymphoid 
cells such as rodent fibroblasts and keratinocytes [65,98,99]. LMP1 is a powerful inducer of 
nuclear factor-κB (NF-κB)-mediated transcription [56,57], a property that is essential for 
EBV-transformed lymphoblastoid cell survival [63]. NF-κB plays a determinant role in cell 
transformation: tumor promotion is mediated by its anti-apoptotic functions and aberrant 
activation of NF-κB is associated with tumorigenesis [80,81]. Moreover, this transcription 
factor is essential for the progression of EBV-associated lymphomas in vivo [100]. Up to date, 
the vast majority of functional studies on LMP1 has used as a prototype B95-8, an infectious 
mononucleosis derived isolate. CAO LMP1, a variant isolated from a NPC, was found to have 
increased potential to transform rodent fibroblasts and to induce tumors in nude mice, when 
compared to B95-8 LMP1 [71], leading to the hypothesis that polymorphisms within LMP1 
gene influences the susceptibility to develop EBV-associated tumors. When compared to 
B95-8 LMP1, CAO LMP1 induces higher levels of NF-κB activation [50]. This observation 
has been extended to several cell types, such as HEK 293, Elijah-BL, Daudi BL, DG75 and 
Jurkat [72], demonstrating that this property is not cell-type specific. However, 
polymorphisms modulating NF-κB activation have not been mapped to date.  
Patients infected with human immunodeficiency virus (HIV) are at high risk of developing 
EBV-associated lymphoproliferative disorders [101]. Earlier, a study of the Swiss HIV 
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Cohort demonstrated that immune responses contribute to the development of EBV-
associated brain lymphoma [102]. However, the contribution of viral factors to the 
development of EBV-associated malignancies is not well understood. EBV has been detected 
in 80-100% of Hodgkin’s lymphoma arising in the setting of HIV, supporting the notion that 
EBV plays a pivotal role in the pathogenesis of this type of tumor [24,103]. Since the 
introduction of highly active antiretroviral therapy (HAART) the number of cancer cases has 
decreased in HIV-infected individuals worldwide. In contrast, the frequency of HL among 
HAART treated HIV-infected patients increases with the prolonged life expectancy 
[24,34,104], suggesting that factors other than HIV-induced immunosuppression are involved 
in the etiology of HL. Of special importance is the detection of EBV type II latency program 
in HL, which is characterized by the expression of LMP1 and two other viral proteins [105]. 
The strong association between EBV and HL in HIV-infected individuals (HIV-HL) and the 
limited number of viral products expressed in the tumor cells provide ideal conditions to study 
the impact of LMP1 genetic variations on the etiology of EBV-associated tumors.  
We mapped several single amino acid polymorphisms leading to significantly enhanced 
capacity for NF-κB activation compared to B95-8 LMP1 and used samples from the Swiss 
HIV Cohort Study (SHCS) to evaluate the importance of LMP1 polymorphisms relevant to 
NF-κB activation in the etiology of EBV-associated HL. 
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MATERIALS AND METHODS 
Samples 
Paraffin blocks of biopsies of B-cell and T-cell lymphomas were provided by the Institute of 
Pathology in Lausanne. One biopsy from a patient with a post-transplant lymphoproliferative 
disorder (PTLD) was obtained from Geneva University Hospital. Biopsies specimen of 
Hodgkin’s lymphoma of HIV-infected individuals were obtained from the Institutes of 
Pathology of the universities of Bern, Geneva, Lausanne and Zurich. Blood samples of HIV-
infected individual were provided by several centers of the SHCS: Bern, Basel, Geneva, 
Lausanne, Lugano and Zurich. This study was approved by the scientific review board of the 
Swiss HIV Cohort Study. All SHCS participants provided informed written consent and the 
SHCS has been approved for Lausanne by the commission cantonale d'éthique de la recherche 
sur l'être humain du canton de Vaud. 
 
DNA extraction  
DNA of tumor samples of B and T cell lymphomas and a case of PTLD was prepared 
according to standard procedures in pathology centers of Lausanne and Geneva. DNA of 
tumor samples from Zurich was extracted at the pathology center of Zurich according to 
standard procedures. Isolation of DNA from biopsies and cell samples of HIV-infected 
individual was performed with QIAamp DNA Mini Kit (QIAGEN, Basel, Switzerland) 
according to manufacturer’s instructions. Frozen biopsies were crushed before DNA 
extraction. Paraffin from paraffin embedded biopsies was removed by dissolution with xylol 
100% before DNA extraction. 
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Amplification by polymerase chain reaction and isolation of LMP1 genes 
The region between positions 169.508 and 168.111 of the EBV genome was amplified using a 
specific primer pair based on the published prototype B95-8 LMP1 sequence [46]. PCRs were 
carried out either with Pwo DNA Polymerase (Roche Applied Science) on the four biopsies of 
EBV-associated tumors (A1, A2, A3 and P1) or with AmpliTaq Gold DNA Polymerase on 
samples from HIV-infected individuals. Primers and PCR programs are available on request. 
PCR products were purified with QIAquick Gel Extraction Kit (QIAGEN) or MSB Spin 
PCRapace (Invitek, Berlin, Germany) and sequenced directly using ABI PRISM BigDye 
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems). The whole gene 
was subcloned into a eukaryotic expression vector, pCR3.1 (Invitrogen, Basel, Switzerland), 
using adapters with HindIII and XbaI restriction sites. At least two independent clones of each 
variant were sequenced on both strands. B95-8 and AG876 full length LMP1 were 
constructed by cloning LMP1 gene from the lymphoblastoid cell lines B95-8 [106] and 
AG876 (kindly provided by A. Rickinson, Birmingham, UK) into pCR3.1 vector. CAO 
variant [71] (kindly provided by F. Grässer, Homburg, Germany) was subcloned into the 
same background vector.  
 
Construction of LMP1 mutants 
Chimeras were built by enzymatic digestion of the gene encoding B95-8, A2 and P1 LMP1s 
using the internal DNA restriction sites NaeI or BglII. Mutations were introduced by PCR 
using Pwo polymerase. All constructs were cloned into the expression vector pCR3.1 and 
sequenced. Plasmids were amplified and purified using Qiagen plasmid MIDI kit (QIAGEN) 
and quantified using NanoDrop ND 1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA).  
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Cell culture  
Human embryonic kidney 293 (HEK) [107] cells were cultured in Dulbecco’s modified Eagle 
medium (DMEM - Gibco, Basel, Switzerland) supplemented with 10% (v/v) heat-inactivated 
fetal bovine serum, penicillin and streptomycin at 37°C with 5% CO2. Lymphoblastoid cell 
lines B95-8 and AG876 were cultured in Roswell Park Memorial Institute medium (RPMI - 
Gibco, Basel, Switzerland) supplemented with 10% (v/v) heat-inactivated FCS, penicillin and 
streptomycin at 37°C with 5% CO2
 
. 
Gene reporter assay 
Gene reporter assay system was used to measure NF-κB activation levels induced by LMP1. 
Expression vectors for either prototype B95-8 LMP1, variants or mutants were co-transfected 
with the reporter κB-conA-luc (kindly provided by F. Grässer) that comprises Firefly 
luciferase gene under the control of a conalbumin reporter with 3 integrated κB elements 
derived from the immunoglobulin κ chain enhancer. HEK cells were transfected in 24-well 
plates with 50 ng of NF-κB Firefly reporter construct κB-conA-luc and 50 ng of LMP1 
expression vectors using FuGENE6 (Roche Applied Science). Twenty-four hours after 
transfection, cells were lysed in Cell Culture Lysis Reagent (Promega, Amriswil, Switzerland) 
and assayed for light emission in a tube luminometer Lumat LB 9507 or a microplate 
luminometer Tristar LB 941 (BERTHOLD TECHNOLOGIES, Bad Wildbad, Germany) 
using Luciferase Assay System (Promega). Final quantifications were calculated on three 
separate experiments performed in triplicates. Statistical analyses were performed using 
GraphPad Prism version 5.04 for Windows (GraphPad Software, http://www.graphpad.com). 
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Immunoblot 
Samples from gene reporter assays were boiled at 95°C for 4 min in 2x sample buffer (62.5 
mM Tris-HCl pH 6.8, 20% glycerol, 2% SDS, 100 mM DTT) and separated through 10% 
SDS-polyacrylamide gel electrophoresis, then transferred to nitrocellulose membrane, probed 
with the appropriate antibodies and revealed by enhanced chemiluminescence (ECL - 
LiteAblot, Euroclone, Italy). Primary antibodies were used at the following dilutions: LMP1 
rat monoclonal 8G3 [108], 1:500 – 1:1.000 (provided by F. Grässer). Mouse anti-alpha-
tubulin (Sigma), 1:10.000. Secondary antibodies were used at the following dilutions: 
Polyclonal rabbit anti-mouse HRP and polyclonal rabbit anti-rat HRP (Dako Cytomation, 
Glostrup, Denmark), 1:4.000 – 1:5.000. 
 
Cell viability 
Toxicity of the different LMP1s was measured using CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega) according to manufacturer’s protocol. This method allows 
determining the amount of viable cells by measuring ATP levels in samples. Briefly, HEK 
cells in 24-well plates were transfected with 50 ng expression plasmids using FuGENE 6. 
Fourteen hours post transfection cells were seed in 96-well plates and twenty-four hours post 
transfection cells were lysed in CellTiter-Glo® Reagent and assessed for luminescent signal 
in a microplate luminometer Tristar LB 941. 
 
Phylogenetic tree 
For phylogenetic analysis, LMP1 nucleotide sequences from position 169474 to 168160 of 
EBV genome were aligned with Geneious (v5.1; A. J. Drummond et al., Biomatters Ltd., 
http://www.geneious.com) and controlled manually for repeats and deletion alignment. The 
alignment was used to build neighbor-joining tree (Jukes-Cantor model) using Geneious.  
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EBV typing 
EBV type was determined on EBNA2 gene as described in Telenti et al.[25]. 
 
Analysis of samples from patients of the SHCS with or without HL 
Among participants of the SHCS, 48 have had a confirmed diagnosis of HL at the date of our 
study. We included in our study 42 HIV-HL with available blood samples (37 men and 5 
women; age at the date of blood sampling 44.2 ± 10.7 years) and 90 SHCS participants 
without any tumor history (72 men and 18 women; age at the date of blood sampling 41.9 ± 
9.2 years). For 16 HIV-HL we obtained blood as well as tumor biopsy. Sequences of LMP1 
gene encoding amino acids 96 to 202 were determined using PCR amplification on genomic 
DNA with AmpliTaq Gold DNA polymerase followed by sequencing with nested primers, 
using the same method as above. Sequences were obtained for 41/42 HIV-HL (36 men and 5 
women, mean age 44.3 ± 10.8 years), for 15/16 biopsies and for 85/90 participants without 
tumor (67 men and 18 women, mean age 42 ± 9.4 years). The strength of the association 
between the two sets of polymorphisms I124V/I152L and F144I/I150A/L151I and the 
etiology of HL was tested with a simple logistic regression and then with a logistic regression 
model controlling for sex, age, CD4 levels and the number of years of antiretroviral therapy at 
the date of blood sampling, using Stata 11 software (StataCorp, http://www.stata.com).  
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RESULTS  
Polymorphism F144I modulates NF-κB activation mediated by variant A2 
Among a panel of LMP1 variants with different abilities to activate NF-κB we selected two 
variants, P1 and A2, on the basis of their activation profile to perform further studies (Figure 
1A). The level of activation of variant P1 is close to that of prototype B95-8 LMP1, whereas 
that of variant A2 has a highly increased level of activation close to that of CAO LMP1. We 
observed that the prototype LMP1 and the two variants were all well expressed (Figure 1B) 
and non-toxic using a cell viability assay (Figure 1C). Furthermore enhanced NF-κB 
activation is not associated with a prolonged half-life, since half-lives of 3.6 ± 0.6 and 2.8 ± 
0.4 hours were determined for P1 and A2, respectively (data not shown). An overview of 
amino acid changes identified in variants P1 and A2 with respect to reference B95-8 LMP1 
[46] is shown in Figure 1D. Variant A2 has a very high overall similarity to CAO LMP1 
[50,71,109].  
We then mapped polymorphisms responsible for the differences in NF-κB activation. In order 
to identify the regions implicated we constructed chimeras between variants and B95-8 
LMP1. In a first set of chimeras, we exchanged the first 231 amino acids of either variant with 
B95-8 LMP1 and constructed the reciprocal chimeras using the same strategy (Figure 2A). 
Functional analysis by gene reporter assay showed that B95-8231/P1 and P1231 /B95-8 activate 
NF-κB at levels close to P1 (Figure 2B). In contrast, B95-8231/A2 and A2231/B95-8 show a 
striking difference in their signaling potential. Whereas B95-8231/A2 induces NF-κB to level 
close to those of the prototype, A2231/B95-8 induces very high level of NF-κB activation, 
close to that of A2. Our results showed that polymorphisms within the 231 N-terminal amino 
acids of A2 are responsible for the increased capacity to activate NF-κB, whilst 
polymorphisms between amino acids 232 and 386, such as the 10 amino acids deletion and 
variations in the direct repeats, do not contribute to the enhanced NF-κB activation 
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phenotype. To better refine regions associated with increased NF-κB activation, we 
exchanged the first 118 amino acids of either variant with B95-8 LMP1, and generated 
reciprocal constructs using the same strategy (Figure 2C). P1118/B95-8 is slightly more 
effective than the reciprocal construct B95-8118/P1 (Figure 2D). Neither B95-8118/A2 nor 
A2118/B95-8 displays the full A2 phenotype. Interestingly, A2118/B95-8 induces levels 
comparable to P1118/B95-8, suggesting that A2 and P1 share polymorphisms in the N-terminal 
part of the molecule (amino acids 1-118) associated with a modest increase in NF-κB 
activation levels with respect to the prototype. NF-κB activation level induced by B95-
8118/A2 is significantly higher than that of the prototype, indicating that one or a combination 
of polymorphisms localized between amino acids 119 and 231 are associated with enhanced 
NF-κB activation. The comparison of the amino acid sequences of variants P1 and A2 within 
residues 1 to 118 shows two common polymorphisms: I85L and F106Y (Figure 1D), which 
were introduced individually in the B95-8 sequence to evaluate their influence. Mutation 
F106Y, but not I85L, is associated with an increase in NF-κB activation level (Figure 2E). 
Interestingly, the single mutation F106Y in the context of B95-8 increases NF-κB activation 
level 3-fold, whereas in the context of chimeras P1118/B95-8 and A2118/B95-8 its effect is 
limited indicating that other polymorphisms located between amino acids 1 and 118 
counteract this effect. We tested the influence of 8 additional polymorphisms present in 
variant A2 between residues 119 and 231 (Figure 1D). Functional analysis of LMP1 mutants 
shows that mutation F144I leads to a significant increase in NF-κB activation (Figure 2E). In 
contrast, other mutations are slightly deleterious (M129I, D150A or L151I) or neutral 
(Q189P, S192T and G212S) (Figure 2E and data not shown). In order to confirm the 
importance of F144I we mutated isoleucine 144 to phenylalanine in variant A2. NF-κB 
activation level induced by A2 I144F is close to that of B95-8 (Figure 2F). In contrast, 
mutation of tyrosine 106 to phenylalanine in variant A2 does not change NF-κB signaling 
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potential of the variant (Figure 2F). These results demonstrate that F144I is the unique 
polymorphism responsible for the high NF-κB activation level mediated by A2.  
 
Figure 1. Analysis of LMP1 variants. (A) NF-κB activation by LMP1 variants. Cells were transfected with 50 
ng of expression vector coding for LMP1 prototype (B95-8) and variants (P1, A3, A1, A2, CAO) and 50 ng of 
Firefly luciferase reporter plasmid. An analogous strategy of subcloning was applied to variants, prototype and 
CAO LMP1, to ensure appropriate comparisons. NF-κB activity was measured twenty hours after transfection 
using luciferase assay (Promega). Data are mean ± SD of triplicates and shown is a representative of three 
independent experiments with similar results. (B) Expression of LMP1 B95-8, A2 and P1 was visualized by 
SDS-PAGE and Western blotting with anti-LMP1 8G3 antibody. Detection against tubulin was used as internal 
control. (C) Measure of the toxicity of LMP1 variants. Cells were transfected with 50 ng of LMP1 B95-8, P1 or 
A2. Untransfected cells and cells transfected with empty vector were used as experimental controls. ATP amount 
was measured 24 hours after transfection using CellTiter-Glo Luminescent Cell Viability Assay (Promega). 
Shown is a representative experiment of three independent experiments with similar results. (D)  Amino acid 
sequence alignment of B95-8, P1 and A2 LMP1. Only amino acids that differ from the sequence of prototype 
B95-8 LMP1 are indicated. Transmembrane segments are indicated by light gray boxes and deletions by dashes. 
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Figure 2. NF-κB activation levels by LMP1 chimeras and mutants. (A, C) Schematic representation of 
LMP1 chimeras split at amino acid 231 (A) and 118 (C). The six transmembrane segments are represented by 
boxes. (B, D-F) NF-κB activation by LMP1 chimeras split at amino acid 231 (B) and 118 (D), and LMP1 
mutants on B95-8 background (E) and on A2 background (F). HEK cells were transfected with 50 ng of LMP1 
vector and 50 ng of NF-κB reporter plasmid. Empty vector was used as control. NF-κB activity was measured 
twenty-four hours after transfection using luciferase assay (Promega). Shown are representative of three 
independent experiments with similar results. Data are given as mean ± SD of triplicates. Statistical analysis was 
done using one-way ANOVA with Bonferroni posttest using GraphPad Prism, n=9 triplicates of three 
experiments. **** P<0.0001 relatively to the NF-κB activation of B95-8 LMP1. RLU: relative light units. 
 
Enhanced LMP1-mediated NF-κB activation is linked to polymorphisms in the 
transmembrane region 
To better understand the importance of polymorphism F144I in the context of LMP1 
sequence variation in individuals without a diagnosis of EBV-associated tumor we 
characterized LMP1 from blood of HIV-infected individuals included in the SHCS. Among 
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randomly chosen genomic DNA, we obtained 31 full length LMP1 genes in a single 
amplification. The frequencies of amino acid changes compared to the B95-8 prototype are 
reported in Figure 3A. F106Y is present in 31/31 variants. The distribution of F144I is more 
restricted (5/31). 14 variants with a 10 amino acids deletion and 2 with a 23 amino acids 
deletion were isolated. A neighbor joining tree was built based on LMP1 nucleotide 
sequences from position 169474 to 168160 of EBV genome. Variants A1, A2, A3 and P1, the 
31 variants isolated from HIV-infected individuals and the references LMP1 B95-8, CAO, 
Raji and AG876 were included in the analysis (Figure 3B). Three different phylogenetic 
groups emerged from the tree. The first group comprising 5 LMP1 variants – 7836, 7885, 
7850, 7825 and 7939– is characterized by two polymorphisms I124V and I152L, which 
always segregate together. The second group includes A2, CAO and the five variants 7924, 
7705, 7950, 7823 and 7910. All variants from the second group are characterized by F144I, 
D150A and L151I and are more closely affiliated to the China1 strain described by Edwards 
et al. than to any other LMP1 strain [109]. The other variants formed a more heterogeneous 
group. Functional analysis revealed that a number of LMP1 variants display enhanced NF-κB 
activation profiles when compared to B95-8 LMP1 (Figure 3C). Variants from the first and 
second groups have all significantly increased capability to activate NF-κB compared to B95-
8 LMP1. A few variants from the third group also display this phenotype. By sequence 
comparisons and directed mutagenesis we identified I124V as the amino acid change 
responsible for enhanced NF-κB activation of  a variant of the first group, 7825 (data not 
shown). As shown above, F144 I is the determinant of the second group of variants. Finally, 
we found that F106Y leads to increased NF-κB activation in the context of variants 7795, 
7815, 7918, 7948 and 7821 of the third group (data not shown). Since we have previously 
shown that this polymorphism has no influence in the context of A2 LMP1 (Figure 2F) and is 
present in all LMP1 variants sequences obtained in this study (Figure 1D and 3A), the effect 
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of F106Y is modulated by sequence variations. To determine whether the phylogenetic 
groups are associated with an EBV subtype, we performed an amplification analysis based on 
the variability in EBNA-2 as described by Telenti and coworkers [25]. Twenty samples 
contained only EBV type 1 and had the same pattern as reference strains B95-8 and Raji; five 
samples contained only EBV type 2 as the reference strain AG876, and 9 samples harbored 
both EBV types (Figure 3D). The analysis showed that both EBV types are distributed among 
the phylogenetic groups and that some samples contained several EBV strains since both 
types were detected simultaneously. In summary, we found two phylogenetic groups of LMP1 
variants characterized by polymorphisms I124V/I152L and F144I/D150A/L151I, 
respectively, and all have an increased ability to activate NF-κB when compared to B95-8 
LMP1. 
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Figure 3. Analysis of LMP1 variants amplified from blood of HIV-infected individuals. (A) Frequency of 
polymorphisms from 31 LMP1 variants compared to the B95-8 prototype reference sequence. Dashes represent 
insertion of amino acids in direct repeats region compared to B95-8. Deletion of 10 (aa 343 to 352) or 23 (aa 332 
to 354) amino acids are present in 13 and 2 variants, respectively. (B) Phylogenetic tree was built on LMP1 
nucleotide sequences by employing neighbor-joining method using Geneious software. (C) Percentages of NF-
κB activation induced by the 31 LMP1 variants. HEK cells were transfected with 50 ng of LMP1 vector and 50 
ng of NF-κB reporter plasmid. NF-κB activity was measured twenty four hours after transfection using luciferase 
assay (Promega). Values were normalized to the B95-8 activation value fixed at 100%. Data are given as mean ± 
SD of percentages of triplicates of three independent experiments. Statistical analysis was done using one-way 
ANOVA with Bonferroni posttest using GraphPad Prism. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 
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relatively to the NF-κB activation of B95-8 LMP1. RLU: relative light units. ND: not done. (D) Typing based on 
EBNA-2 gene was performed on genomic DNA according to Telenti and coworkers [25]. B95-8 and Raji are 
EBV type 1 references and AG876 is EBV type 2 reference. 
 
Polymorphisms I124V/I152L and F144I/D150A/L151I are not associated with HIV-HL 
Since LMP1 driven NF-κB activation is essential for EBV-transformed cells survival, we 
tested whether enhanced NF-κB activation potential favors the etiology of EBV-associated 
HL. We analyzed samples from HIV-infected individuals enrolled in the SHCS who have had 
a diagnosis of HL or not in a pilot epidemiological study (Figure 4A). At the time of our study 
forty-eight HL were diagnosed among participants of the SHCS and blood samples from 42 
participants were available. Blood samples from 90 participants without tumor diagnosis were 
used as comparators. To determine the presence of the relevant polymorphisms we amplified 
and sequenced a region of LMP1 gene corresponding to amino acids 96 to 202 (Figure 4A 
and Materials and Methods). Among the 41 HIV-HL with LMP1 amplification and sequence 
we detected single sequences in samples from 31 participants and two sequences in samples 
from 10 participants. Among the 85 participants without tumor diagnosis with LMP1 
amplification and sequence we detected single sequences in samples from 36 participants, two 
sequences in samples from 46 participants and three sequences in samples from 3 participants.  
We assessed the presence of polymorphisms I124V/I152L and F144I/D150A/L150I for each 
participant’s sample (Table 1). I124V/I152L was found in 12.2% of HIV-HL and in 24.7% of 
participants without tumor. F144I/D150A/L150I was found in 41.5% of HIV-HL and in 
31.8% of participants without tumor. The simultaneous presence of both sets of 
polymorphisms was found in blood from one HIV-HL and from four participants without 
tumor. The strength of the association between the polymorphisms of interest and the etiology 
of HL was tested with a simple logistic regression and then with a logistic regression model 
adjusted for sex, age, CD4 levels and the number of years of antiretroviral therapy at the date 
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of blood sampling (Table 2). Our results showed that I124V/I152L and F144I/D150A/L151I 
are not associated with HL development neither in the simple and nor in the multivariable 
analyses.  
 
Figure 4. Flow chart of the study. (A) Comparison of LMP1 polymorphisms in blood samples from HIV-
infected individuals with or without HL. *patients enrolled in the SHCS at the beginning of the study by March 
2009 [110]. (B) Comparison of LMP1 polymorphisms in blood and corresponding biopsy from HIV-HL. 
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Table 1. Comparison of LMP1 polymorphisms in blood from HIV-HL and from HIV-
infected individuals without tumor  
Polymorphisms Frequency %
Sequences obtained from samples of 41 HIV-HL
† 
I124V/I152L 
* 
5 12.2 
F144I/D150A/L151I 17 41.5 
Other 20 48.8 
Sequences obtained from samples of 85 participants without tumor
I124V/I152L 
§ 
21 24.7 
F144I/D150A/L151I 27 31.8 
Other 41 48.2 
* Single sequences were obtained from 31 participants and 2 sequences from 10 participants. 
§ Single sequences were obtained from 36 participants, 2 sequences from 46 participants and 3 sequences from 3 
participants. 
† The total is more than 100% due to the simultaneous presence of both sets of polymorphisms in 1 HIV-HL and 
in 4 participants without tumor. 
 
 
Table 2. Association between the presence of polymorphisms I124V/I152L or 
144I/D150A/L151I and HIV-HL susceptibility measured by logistic regression 
Polymorphisms OR 95% CI OR 95% CI* 
I124V/I152L 
* 
0.42 [0.15 / 1.22] 0.44 [0.14 / 1.39] 
F144I/D150A/L151I 1.52 [0.70 / 3.29] 1.25 [0.52 / 3.00] 
I124V/I152L and 144I/D150A/L151I 0.98 [0.46 / 2.06] 0.78 [0.33 / 1.82] 
* Adjusted for sex, age, number of years of antiretroviral therapy, CD4 levels, all at the date of blood sampling. 
 
We further analyzed the distribution of the relevant polymorphisms in the corresponding 
biopsies from 16 HIV-HL (Figure 4B). LMP1 sequences were obtained from 15/16 biopsies, 
among them single sequences were obtained in biopsies from 10 participants and two 
sequences in biopsies from 5 participants. We found a good concordance between LMP1 
sequences from HIV-HL biopsies and corresponding blood in 10/15 cases (Table 3). As a 
second marker we used EBV subtype based on EBNA2 differences. We were able to type 
EBV from the blood of 15 HIV-HL and from 12 biopsies and the data overall confirm the 
good concordance between blood and biopsy.   
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Table 3. Comparison of LMP1 polymorphisms and EBNA2 subtype in blood and in the 
corresponding biopsy of HIV-HL 
Cases Sequences obtained EBV subtype*
# 
  
Sample # LMP1  Polymorphisms Identical sequences   
1 Blood 2 Others  1 
 Biopsy 1 Other Yes NA 
2 Blood 1 V124  1+2 
 Biopsy 1 Other No 1 
3 Blood 1 I144  1 
 Biopsy 1 I144 Yes NA 
4 Blood 1 Other  2 
 Biopsy 1 Other Yes 2 
5 Blood 1 Other  1 
 Biopsy 1 Other Yes 1 
6 Blood 1 I144  2 
 Biopsy 2 I144 - Other Yes 2 
7 Blood 1 I144  2 
 Biopsy 2 I144 - Other Yes 1+2 
8 Blood 1 Other  1+2 
 Biopsy 1 Other No 1+2 
9 Blood 1 Other  1+2 
 Biopsy 1 Other Yes 1+2 
10 Blood 2 I144  1+2 
 Biopsy 1 I144 Yes 1 
11 Blood 1 Other  1+2 
 Biopsy 1 Other No 1+2 
12 Blood 1 Other  1+2 
 Biopsy 2 V124 - I144 No 2 
13 Blood 1 Other  NA 
 Biopsy 0 NA NA NA 
14 Blood 1 I144  1 
 Biopsy 1 I144 Yes 1 
15 Blood 1 I144  1 
 Biopsy 2 Others No NA 
16 Blood 1 Other  1 
 Biopsy 1 Other Yes 1 
NA: not amplified 
* based on EBNA2 differences 
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DISCUSSION 
In the present study polymorphisms leading to enhanced LMP1-mediated NF-κB activation 
were identified and their importance in the etiology of EBV-associated HIV-HL was assessed 
in a pilot epidemiological study. Overall, the results presented here improve the understanding 
of the landscape of LMP1 genetic variation associated with NF-κB activation and show that 
markers of increased NF-κB activation levels in vitro are not predictive factors for EBV-
associated HIV-HL susceptibility in the SHCS. 
Since the initial description of LMP1 variant CAO isolated from a NPC [71], it has been 
hypothesized that LMP1 polymorphisms influence the development of EBV-associated 
diseases. Previous studies reported LMP1 sequence variations [74,75,109,111] and 
differences in the extent of NF-κB activation for some variants [50,72,112]. Induction of 
higher NF-κB activation levels by CAO LMP1 compared to B95-8 LMP1 was consistently 
observed in several cell lines of B cell and epithelial origin when measured by reporter assays 
[50,72,111,112]. In addition, CAO LMP1 was more oncogenic than B95-8 LMP1 in a nude 
mice model by inducing phenotypic changes in a non-tumorigenic human keratinocyte line 
[66]. This led us to test whether polymorphisms responsible for increased LMP1-mediated 
NF-κB activation levels in vitro were associated with the etiology of HIV-HL.  
The risk of HL in HIV-infected individuals is significantly higher than in the general 
population [34]. The use of HAART that improved the immunity status of HIV-infected 
individuals is associated with reduced incidence of Kaposis’s sarcoma and high grade non-
Hodgkin’s lymphoma, but paradoxically with an increased risk of HIV-HL [33]. Moreover, 
HL risk could not be associated with absolute CD4+ 104 cell counts [ ]. Hodgkin’s lymphoma 
arising in HIV-infected individuals show distinctive features compared to the HL cases in the 
general population, among them the association of HIV-HL with EBV in almost all cases 
[24,103,113]. The high frequency of EBV association with HIV-HL and the detection of a 
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strong expression of LMP1 in tumor tissue in the context of a type II latency pattern 
[24,114,115] indicate that LMP1 is a relevant factor involved in the pathogenesis of this 
disease. Additional evidences highlight the central importance of the NF-κB signaling 
pathway for pathogenesis: NF-κB activation by LMP1 is critical for B cell transformation in 
vitro and in vivo [97,100,116,117,118], NF-κB hyperactivity was shown to be associated with 
tumorigenesis [119] and mutations in NF-κB regulatory pathways leading to increased 
activity have been identified in EBV-negative HL [120,121,122].  
In this study LMP1 variants isolated from HIV-infected individuals living in Switzerland 
were characterized with respect to their sequence variations and their NF-κB activation 
potential measured by gene reporter assay. The increased EBV load in blood samples from 
HIV infected individuals [25,26] allowed the amplification of the LMP1 gene as a single 
fragment, an essential step to avoid PCR-driven recombination between EBV strains in 
samples with multiple EBV infection. Overall our analysis gives a new insight into LMP1 
sequence variation in individuals without a diagnosis of EBV-associated tumor. 
Concomitantly we found that a number of variants mediate higher NF-κB activation levels 
when compared to the prototype B95-8 LMP1 and mapped several polymorphisms that have 
an effect on signaling. Single amino acid change F144I is present in variants that cluster with 
CAO in a phylogenetic analysis and that have the ability to activate NF-κB at high levels. 
This group, characterized by amino acid changes F144I/D150A/L151I, is more closely related 
to China1 than to the other LMP1 strains with F144I described by Edwards et al. [109,112]. 
Another amino acid change associated with enhanced NF-κB activation is I124V, present in 
group of variants characterized by polymorphisms I124V/I152L that have not been previously 
described. The last amino acid change we found associated with enhanced NF-κB activation 
is F106Y. This polymorphism is present in all LMP1 variants isolated in our study and its 
effect is counteracted in most variants by one or several polymorphisms that have not yet 
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been mapped. Thus F106Y could not be used to predict NF-κB activation levels. Taken 
together our results demonstrate that several groups of LMP1 variants, through distinct 
mutational paths, mediate enhanced NF-κB activation levels compared to B95-8 LMP1 and 
point out the transmembrane segments 4 and 5 for their importance on NF-κB modulation. 
Polymorphisms I124V/I152L and F144I/D150A/L151I were chosen as markers of enhanced 
NF-κB activation in a pilot epidemiological study within the SHCS. By comparing LMP1 
variants present in blood of SHCS participants with or without HL diagnosis, we observed 
that I124V/I152L and F144I/D150A/L151I, combined, were found in more than 50% of the 
participants from each group. Concordant with a high distribution in the two groups of 
patients, the two sets of polymorphisms are not identified as predictive factors associated with 
HL etiology when analyzed by a logistic regression model, either together or individually. 
However, a lower percentage of I124V/I152L in samples from HIV-HL compared to samples 
from individuals without tumors (12.2% versus 24.7%) was observed, and in parallel, a higher 
percentage of variants with F144I/D150A/L151I (41.5% versus 31.8%). More than one 
variant was detected in some samples, as demonstrated by EBV typing based on EBNA-2 
gene and analysis of LMP1 sequences. The percentage of samples presenting a co-infection 
by EBV type 1 and type 2 was concordant with what was previously reported in the literature 
[123]. The presence of distinct EBV strains in the blood and tumor site has been previously 
reported [124]. In contrast, another study showed a good concordance with respect to EBNA-
2 region and LMP1 gene in normal and neoplastic cells [125]. In order to determine to which 
extend EBV strains differ between blood and tumor biopsy samples on a larger group of 
patients, we further compared LMP1 sequences present in blood from HIV-HL and in its 
corresponding biopsy. EBV typing based on EBNA-2 was chosen as an additional marker. 
Using these two criteria we found a good correspondence between blood and tumor samples 
in 10/15 cases. The major limit of this study is the low number of HL cases in the SHCS and 
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the low number of available biopsies. The relatively good correspondence of LMP1 variants 
between blood and tumor biopsies indicates that larger future studies using blood samples 
would be relevant to the identification of viral polymorphisms influencing the development of 
EBV-associated malignancies.  
Further studies will be needed to find out the complex effects of LMP1 variants in tumor cells 
in the context of EBV latency type II program.  Our results extend the previous observations 
made on CAO LMP1 and demonstrate that several groups of LMP1 variants through distinct 
mutational paths mediate increased NF-κB activation levels in vitro. Moreover, naturally 
occurring polymorphisms that lead to enhanced NF-κB activation in vitro are not identified as 
risk factors associated with HIV-HL susceptibility.   
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3.2 CHAPTER 1 - SUPPLEMENTARY FIGURES AND METHODS 
3.2.1 DETERMINATION OF PROTEIN HALF-LIFE BY PULSE CHASE ANALYSIS 
HEK cells were transfected in 100-mm plates with 2 μg of the expression plasmids using 
Fugene 6. 24 hours post-transfection cells pooled from two 100-mm plates were seeded in six 
60-mm plates coated with poly-L-Lysine and grown for 14 hours. Cells were starved at 37°C 
for 30 minutes in methionine and cysteine-free DMEM supplemented with 2% FCS and 
pulse-labeled with 100 μCi [35
 
S] labeled cysteine/methionine per ml (Hartman) at 37°C for 45 
minutes. Cells were washed with complete medium and then replaced in the incubator with 
complete DMEM for incubation from 0 to 12 hours chase times. Cells were rinsed with 
chilled PBS and lysed in RIPA buffer (150 mM NaCl, 20 mM Tris-HCl pH 8, 0.5% sodium 
deoxycholate, 1% Triton X-100, 0.1% SDS) supplemented with inhibitors of proteases 
(minicomplete, Roche Applied Science) and inhibitors of phosphatases (20 mM NaF, 25 mM 
glycerophosphate, and 1 mM orthovanadate). Lysates were cleared by centrifugation at 
16,000g for 10 minutes and deep frozen in nitrogen at each time point. Samples were 
immunoprecipitated with mouse anti-LMP1 S12 monoclonal antibody bound to protein-A 
sepharose for 2 hours at 4°C. Precipitates were washed three times with RIPA buffer and 
twice with phosphate buffered saline and boiled for 4 min in 50 μl of 2x sample buffer and 
separated by 10 % SDS-PAGE. Gels were dried, exposed on a phosphor screen cassette and 
then the signal was read with a Typhoon (Amersham Biosciences) and quantification was 
done using ImageQuantTM TL2005 software (Amersham Biosciences). 
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Supplementary Figure 1: Determination of the half-life of B95-8, A2 and P1 LMP1. (A) Comparison of the 
expression of B95-8 LMP1 upon plasmid transfection in 293T cells and upon natural expression in B95-8 LCL. 
For the transient transfection 293T cells were transfected with 50 ng of B95-8 LMP1 vector. B95-8 LCL cells 
were grown in RPMI. Both kinds of samples were lysed and the protein amount measure with BCA (Pierce). 
B95-8 LCL sample was serially diluted with H2O. Samples were then separated on a 10% SDS PAGE and 
immunobloted with S12 anti-LMP1 antibody. (B) Scan of the radioactive signals. (C) Plotted quantifications of 
the signals detected in A and determination of the half-life with a non-linear regression model using GraphPad 
Prism version 5.03 for Windows. (D) Histogram of the half-life and values. 
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3.2.2 NF-ΚB ACTIVATIONS LEVELS OF LMP1 PROTOTYPE AND MUTANTS  
 
Supplementary Table 1: 
NF-κB activation levels of LMP1 prototype and mutants.  
 
 
 
 
 
 
 
 
 
 
 
NF-κB activities were measured 24 hours after transfection. Values are percentages ± SD of means of 9 
independent transfections normalized to the activity of B95-8 LMP1 fixed at 100%. Significant p-values 
compared to the activation of B95-8 LMP1 are indicated with asterisks (p<0.05, one-way ANOVA with 
Bonferroni posttest performed using GraphPad Prism version 5.03 for Windows, GraphPad Software, San Diego 
California USA, www.graphpad.com). 
 
  
LMP1 % SD % p-value 
Prototype B95-8 100 0  
Mutants 
B95-8 I85L 101 48 ns 
B95-8 F106Y 296 114 *** 
B95-8 L126F 93 35 ns 
B95-8 M129I 76 24 ns 
B95-8 F144I 308 108 *** 
B95-8 D150A 83 12 ns 
B95-8 L151I  64 22 ns 
B95-8 Q189P 87 15 ns 
B95-8 S192T 115 23 ns 
B95-8 G212S 87 41 ns 
B95-8 F106Y 289 38 *** 
B95-8 F144I 334 30 *** 
 A2 Y106F 448 60 *** 
 A2 I144F 167 10 ns 
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3.2.3 INVOLVEMENT OF POLYMORPHISMS 124-152 AND 106 FOR NF-ΚB ACTIVATION 
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Supplementary Figure 4: NF-κB activation. (A-B) NF-κB activation by LMP1 mutants on B95-8 background 
and on variants background. HEK cells were transfected with 50 ng of LMP1 vector and 50 ng of NF-κB 
reporter plasmid. Empty vector was used as control. NF-κB activity was measured twenty-four hours after 
transfection using luciferase assay (Promega). Shown are representative of three independent experiments with 
similar results. Data are given as mean ± SD of triplicates. Statistical analysis was done using one-way ANOVA 
with Bonferroni posttest using GraphPad Prism. ** P<0.01, *** P<0.001 relatively to the NF-κB activation of 
B95-8 LMP1. RLU: relative light units. (A) LMP1 mutants with positions 124 and 152 mutated in B95-8 and 
variant in 7825, a member of the first group of variants. (B) LMP1 mutants with position 106 mutated in B95-8 
and in LMP1 variants of the third group. 
 
3.2.4 PRIMERS AND PCR CONDITIONS FOR LMP1 AMPLIFICATION FROM GENOMIC DNA 
The region between positions 169.508 and 168.111 of EBV genome was amplified using a 
pair of primers based on the published prototype B95-8 LMP1 sequence [46]:  
Fwd: 5’-TCAACTGCCTTGCTCCTGACAC-3’  
Rev: 5’-AGGCAAGCCTATGACATGGTAATGC-3’.  
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PCRs were carried out either with Pwo DNA Polymerase (Roche Applied Science): [98°C  
5 min, 5 cycles (94°C 1 min, 65°C 1 min, 72°C 1.5 min), 5 cycles (94°C 1 min, 63°C 1 min, 
72°C 1.5 min), 25 cycles (94°C 1 min, 60°C 1 min, 72°C 1.5 min), 5 cycles (94°C 1 min, 
57°C 1 min, 72°C 1.5 min), 72°C 10 min] or with AmpliTaq Gold DNA Polymerase (Applied 
Biosystem): [95°C 10 min, 5 cycles (95°C 1 min, 65°C 1min, 72°C 1.5 min), 5 cycles (94°C  
1 min, 63°C 1min, 72°C 1.5 min), 25 cycles (95°C 1 min, 60°C 1min, 72°C 2 min), 5 cycles 
(95°C 1 min, 57°C 1 min, 72°C 1.5min), 72°C 10 min] on the four biopsy samples used for 
the mapping of the polymorphisms and samples from HIV-infected individuals, respectively.  
 
3.2.5 EBV TYPING 
EBV type was determined on EBNA2 gene by performing PCR and nested PCR on this gene 
with AmpliTaq Gold® DNA Polymerase (Applied Biosystems, Rotkreuz, Switzerland). 
Primers and PCR program used in our study are based on the publication of Telenti et al. [25]: 
Common forward primer: 5’-AGGGATGCCTGGACACAAGA-3’ 
Common reverse primer:   5’-TGGTGCTGCTGGTGGTGGCAAT-3’ 
EBV-1 forward nested primer:  5’-TCTTGATAGGGATCCGCTAGGATA-3’ 
EBV-1 reverse nested primer:  5’-ACCGTGGTTCTGGACTATCTGGATC-3’         
EBV-2 forward nested primer:  5’-CATGGTAGCCTTAGGACATA-3’      
EBV-2 reverse nested primer:  5’-AGACTTAGTTGATGCCCTAG-3’ 
PCR were carried out with this program: [94°C 10 min, 30 cycles (94°C 1.5 min, 60°C 1 min, 
72°C 2 min), 72°C 10 min]. 
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4.1 CHAPTER 2 - INTRODUCTION 
Epstein-Barr virus (EBV), the etiological agent of infectious mononucleosis, is an important 
human oncogenic virus being implicated in the pathogenesis of several malignancies 
including nasopharyngeal carcinoma, Burkitt’s lymphoma, nasal NK/T cell lymphoma, 
Hodgkin’s lymphoma and post-transplant lymphoproliferative disorders [126]. EBV is a 
ubiquitous gammaherpesvirus that can infect multiple cell types including B cells, which 
provide a reservoir for the virus [127,128]. EBV infection of B-lymphocytes is mostly latent 
and results in the expression of a limited number of nuclear and membrane proteins. Latent 
membrane protein 1 (LMP1), which is detected in tumor cells of human malignancies 
associated with EBV, is a multifunctional oncogene with potent transforming effects in cell 
culture and animal models. LMP1 has transforming effects on non-lymphoid cells such as 
rodent fibroblasts and keratinocytes [65,98,99], is essential for EBV-induced B-cell 
transformation and in vitro transformation [95,96,97] and causes lymphoma in transgenic 
mice [67].  LMP1 is a powerful inducer of nuclear factor-κB (NF-κB)-mediated transcription 
[56,57], a property that is indispensable for EBV-transformed lymphoid cell survival in vitro 
and in vivo [63,100,116]. 
LMP1 is an integral membrane protein with a short cytoplasmic N-terminus, six 
transmembrane-spanning segments (TMs) and a 195 amino acids long C-terminal domain 
[45,46]. Two motifs within the cytoplasmic C-terminal domain of the protein are essential for 
NF-κB activation and cell transformation. The first motif, designated as C-terminal activating 
region 1 (CTAR1), spans residues 199-231, interacts with TRAF1-6 
[53,55,129,130,131,132,133,134]. The second motif, CTAR2, is located between residues 
352-386 [130,133]. This region of LMP1 is thought to mediate NF-κB activation through 
direct binding of the TNF-associated death domain protein (TRADD), which interacts with 
TRAF2, thus mimicking TNF-receptor 1 (TNFR1)-mediated NF-κB activation [135,136]. 
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This region is also linked to the activation of the AP-1 family of transcription factors through 
the c-Jun N-terminal kinase (JNK) pathway [59,137,138].  
LMP1 acts as a constitutively active receptor-like molecule that mimics CD40 and alters cell 
growth [54,95,139]. However, unlike members of the tumor necrosis factor receptor (TNFR) 
family, LMP1 signals in a ligand-independent fashion, a feature that is largely due to the 
properties of its TMs. Indeed chimeric proteins with LMP1’s amino terminus and membrane-
spanning segments fused to the carboxy-terminal signaling domain of TNFR-1, TNFR-2 and 
CD40 signal in the absence of ligand, whereas chimeric proteins with extracellular ligand 
binding domain of cell surface receptors fused to LMP1’s carboxy terminus are activated in a 
ligand-dependent manner [54,140,141,142]. However, the relative contribution of the six TMs 
to the many functional properties of LMP1 is not well understood. In the present study we 
have constructed series of LMP1 mutants with either four or two TMs to evaluate the relative 
importance of the three pairs of TMs for membrane association, self-association, binding to 
cellular factors and modulation of NF-κB activation. Our results show that LMP1 TMs are 
implicated in a number of functions, some of which have not been described before. Notably, 
the three pairs of TMs and the two intracellular loops that link them are not functionally 
equivalent and interchangeable. Overall, the transmembrane domain of LMP1 is a key player 
in protein-protein interactions and signaling.   
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4.2 CHAPTER 2 - RESULTS 
4.2.1 LMP1 TMS MUTANTS 
LMP1 is an integral membrane protein with six transmembrane spanning domains (TMs) 
(Figure 1A) [46]. In contrast to the N- and C-terminal domains of LMP1, which were the 
focus of many studies, much less is known about TMs. It has been demonstrated that LMP1 
acts as a constitutively active receptor by means of aggregation mediated by the TMs. 
However the question of the relative importance of the six segments has not been addressed 
before in comparative experiments.  
To better understand the role of each pair of TMs we constructed LMP1 mutants with either 
four or two TMs (Figure 1B-C). These TMs mutants allowed us to analyze the contribution of 
the three pairs of TMs to self-association, binding to the cellular partners TRAF3 and β-TrCP, 
and NF-κB activation. Finally, the naturally occurring polymorphisms identified in LMP1 
TMs will be presented in the perspective of these biochemical analyses. 
LMP1 mutants with four TMs are schematically represented in Figure 1B. TM3-4-5-6 
comprises the LMP1 N-terminus fused to TMs 3 to 6 and the C-terminal domain. The two 
constructs TM1-2+5-6 (L2) and TM1-2+5-6 (L4) differ only in the intracellular loops L2 or 
L4 that link the TM pairs and comprise LMP1 N-terminus fused to the TMs 1-2 and TMs 5-6, 
followed by the C-terminus. Finally, TM1-2-3-4 encodes LMP1 N-terminus fused to the TMs 
1 to 4 and the C-terminal domain. LMP1 mutants with two TMs harbor a single pair of TMs 
fused to the N- and C-terminal domains (Figure 1C). Importantly, all TMs mutants contain 
identical N- and C-terminus for optimal comparisons. 
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Figure 1: Schematic representation of LMP1 B95-8 prototype and transmembrane mutants. The TMs are 
indicated by small boxes and numbered 1 to 6. The loops that link the TMs are numbered L1 to L5. (A) B95-8 
LMP1 prototype contains 6 TMs and 5 loops. (B-C) LMP1 TMs mutants were constructed by PCR-driven 
mutagenesis. All TMs mutants have identical N- and C-terminus. (B) TMs mutants with four TMs. The only 
difference between TM1-2+5-6(L2) and TM1-2+5-6(L4) is the intracellular loop 2 or 4. (C) TMs mutants with 
two TMs. 
 
4.2.2 LMP1 MUTANTS WITH 4 TMS ASSOCIATE WITH THE PLASMA MEMBRANE  
LMP1 is inserted in the membrane thanks to the first TM, which plays the role of leader 
sequence, and to the cytoplasmic N-terminus that provides the structural information whereby 
proper membrane orientation is achieved [87]. To confirm the membrane association of the 
different LMP1 constructs, we performed a subcellular fractionation of cells transfected either 
with LMP1 B95-8, TMs mutants or C-GFP (Figure 2 and 5G for C-GFP scheme). The 
transmembrane transferrin receptor and caspase-3 were chosen as membrane and cytoplasmic 
markers, respectively. The transferrin receptor was recovered in the pellet containing 
membrane proteins, whereas the caspase-3 was detected in the supernatant only, confirming 
the quality of the fractionation. C-GFP consists of the C-terminal part of LMP1 fused to 
EGFP. As expected this construct, which lacks TMs, was exclusively found in the 
cytoplasmic fraction. All TMs mutants with 4 TMs were fully associated with the membrane. 
In contrast, mutants TM3-4 and TM5-6 were found both in the membrane and in the 
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cytoplasmic fractions. This analysis showed that the three pairs of TMs were not equivalent 
with respect to membrane insertion and that multiple TMs were required for optimal 
membrane association. 
  
Figure 2: Multiple TMs ensure membrane association. 293T cells transfected with expression vectors coding 
for B95-8 LMP1 or LMP1 transmembrane mutants were homogenized and fractionated as described in Materials 
and Methods. The proteins present in the membrane (M) and the cytoplasmic (C) fractions were analyzed on 
10% SDS-PAGE. LMP1, transferrin receptor (TR) and caspase-3 (casp-3) were detected using the appropriate 
antibodies. IB: immunoblot. 
 
4.2.3 EACH PAIR OF LMP1 TMS CONTRIBUTED TO SELF-ASSOCIATION 
LMP1 is a functional mimic of the cellular receptor CD40 [54,95,139]. However, unlike 
members of the tumor necrosis factor (TNFR) family, LMP1 signals in a ligand-independent 
fashion, a feature that is attributed to the properties of its six TMs. TM 1 is thought to play a 
special role in this process due to the presence of a leucine heptad [143] and residues FWLY 
[94].  
We tested the relative ability of the three TMs pairs to mediate interactions in  
co-immunoprecipitation (co-IP) experiments. Flag-tagged and HA-tagged versions of B95-8 
LMP1 (Figure 3A) and mutants with one pair of TMs were constructed and co-expressed in 
HEK cells. After cell lysis, HA-tagged LMP1 was immunoprecipitated and the associated 
Flag-tagged molecules subsequently revealed by immunoblotting.  
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B95-8 LMP1 strongly associated with itself in co-IP experiments even using a stringent buffer 
for cell lysis, binding and washing (Figure 3B lane 4). The analysis of LMP1 mutants with a 
single pair of TMs showed that each mutant was able to associate with itself (Figure 3B lane 
5-7), the strongest association being between mutants containing TMs 3 and 4. Interestingly 
the three TMs mutants were also able to associate with each other (Figure 3B lane 8-10), the 
weakest association was seen between TM1-2 and TM5-6, whereas TM3-4 and TM5-6 
associated more strongly. 
In summary, these results demonstrated that TMs 1 and 2 did not play a unique role in self-
association. Indeed, the comparative analysis showed that TMs 3 and 4 probably played a key 
role in association. 
 
Figure 3: LMP1 association occurs through its TMs. (A) Schematic representation of HA- and Flag-tagged 
B95-8 LMP1. (B) Association of HA- and Flag-tagged LMP1. HEK cells were transfected with HA- and Flag-
tagged LMP1 constructs. Cells were lysed 38h later and extracts were immunoprecipitated with anti-HA 
antibody bound to protein A Sepharose. LMP1 immunoprecipitates (IP) and cells lysates were resolved by SDS-
PAGE and analyzed by immunoblotting (IB) using the indicated antibodies. NT: non-transfected; pCR3.1: 
empty vector. 
 
4.2.4 TRAF3 BINDING REQUIRED THE 6 TMS OF LMP1  
TNF receptor-associated factor 3 (TRAF3) was first described as a CD40-interacting 
molecule [144,145,146] and simultaneously as a cellular interacting factor of LMP1 [55]. 
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TRAF3 is the best characterized cellular partner of LMP1. The exact role of TRAF3 in CD40 
and LMP1 signaling remained elusive for many years. Recent studies reveal major functions 
played by TRAF3 in the alternative NF-κB signaling and the control of type I interferon 
production [147].  
LMP1 binds TRAF3 through the PxQxT motif of CTAR1 (Figure 4A) [131,148]. As shown 
in the control experiment, CTAR1- and CTAR1-/2- mutants harboring a mutated TRAF 
binding site lost the ability to bind endogenous TRAF3 in co-IP experiments (Figure 4A-B). 
We further tested the impact of the deletion of one or two pairs of TMs on TRAF3 
association. Co-IP experiments showed that the deletion of a single pair of TMs had a major 
impact on TRAF3 binding (Figure 4C-D). These results extended a previous observation 
showing that LMP1 mutant containing only TMs 1 and 2 does not interact detectably with 
TRAF3 [148]. Interestingly, these data revealed that the deletion of any pair of TMs had a 
similar effect on TRAF3 binding. Since the PxQxT motif was conserved in all TMs mutants 
the loss of TRAF3 binding was likely the result of conformational changes and loss of 
aggregation. 
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Figure 4: TRAF3 binding requires LMP1 six TMs. (A) Schematic representation of LMP1 B95-8 and CTAR 
mutants. Mutations in the CTAR1 and CTAR2 sites are indicated. (B-C-D) Co-IP of endogenous TRAF3 with 
B95-8 LMP1 and mutants. 293T cells were transfected with LMP1 constructs, lysed 38h later and extracts were 
immunoprecipitated with S12 anti-LMP1 antibodies bound to protein A Sepharose. LMP1 immunoprecipitates 
(IP) and cells lysates were resolved by SDS-PAGE and analyzed by immunoblotting (IB) using the indicated 
antibodies. Endogenous TRAF3 binding to (B) CTAR mutants, (C) TMs mutants with 4 TMs and (D) TMs 
mutants with 2 TMs. pCR3.1: empty vector. 
 
4.2.5 Β–TRCP BINDING REQUIRED LMP1 TMS 3 AND 4  
In constrast to TRAF3, which was the focus of many studies, little is known about the 
interaction between LMP1 and the cellular β-transducing-repeat containing protein (β-TrCP). 
LMP1 was shown to associate with β-TrCP2 [82]. This binding was proposed to occur 
through a canonical DSG binding site close to the TRAF binding site (Figure 5A) and a 
cryptic site comprising S350 and S366 [82]. Mainou et al. confirmed a binding between 
natural LMP1 variants and β-TrCP2, but showed that this interaction is more complex than 
previously described by Tang et al. [112] and probably involved alternative binding sites.  
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To better understand this interaction, we constructed DSG mutants by mutating the canonical 
and cryptic β-TrCP2 recognition site in LMP1 to create DSGm1 (G212S/Δ346-355/S366T), 
DSGm2 (mutation of the two serines S211A/S215A of the DSGxxS site) and DSGm3 
(D210N/S211A/E214Q/S215A/D216N) (Figure 5A). DSGm1 resembled the triple mutant 
used by Tang et al. [82]. Co-IP experiments of DSG mutants with β-TrCP2 showed that all 
DSG mutants interacted with β-TrCP2 as B95-8 LMP1 (Figure 5B). These results showed that 
the DSG binding motif was not the major β-TrCP2 binding site of LMP1. We further tested 
whether the loss of TRAFs binding interfered with β-TrCP2 binding. Both CTAR1- and 
CTAR1-/2- bound β-TrCP2 as B95-8 LMP1. It is to note that in all the co-IP experiments we 
observed a weaker detection of β-TrCP2 in cell lysates when co-transfected with the empty 
vector, than when co-transfected with the different LMP1 constructs (Figure 5). 
By controlling the substrate specificity, β-TrCP2 is a key subunit of the SCF E3β-TrCP2
78
 
ubiquitin ligase complex. Via the N-terminal F-box domain β-TrCP2 binds to Skp-1 and via 
the C-terminal WD40 domains to the phosphorylated substrates [ ]. To test the direct 
interaction of β-TrCP2 with LMP1 we used a construct encoding the WD40 domains of  
β-TrCP2 and lacking the F-box domain in co-IP experiments. The results showed that LMP1 
is able to co-immunoprecipitate both full length β-TrCP2 and its WD40 domains (Figure 5C-
D). A similar result was found in the reciprocal experiment (Figure 5E). These findings 
demonstrated that the interaction between LMP1 and β-TrCP2 was mediated by the WD40 
domains and did not involve other subunits of the SCF complex.  
In humans, β-TrCP family includes two homologous proteins, β-TrCP1, encoded by BTRCP, 
and β-TrCP2, encoded by FBXW11, also known as HOS [78,149,150]. The WD40 domains of 
β-TrCP1 and β-TrCP2 are highly homologous and show similar electrostatic surface 
properties with a conservation of the central groove covered by positively charged amino 
acids [84]. Consistently, HIV-encoded Vpu protein was shown to interact with both β-TrCP1 
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and β-TrCP2 [84]. We showed that β-TrCP1 bound B95-8 LMP1 (Figure 5F), a result 
providing an additional example of a functional redundancy of the two homologous proteins.  
In a first approach to define the LMP1 regions involved in the interaction, we used LMP1 
mutants with deletions of the entire N- or C-terminal domains and of the TM domain (Figure 
5G). Mutants were tagged with EGFP and Flag to allow expression and detection. Mutants  
N-TM-GFP and TM-GFP bind to WD-β-TrCP2, whereas C-GFP and C232
To dissect the involvement of each pair of TMs in β-TrCP2 binding we performed co-IP 
experiments with TMs mutants. An association with β-TrCP2 was observed for LMP1 
mutants containing TMs 3 and 4 (Figure 5I lanes 3 and 6; Figure 5J lane 4), but was lost for 
the mutants lacking these two TMs (Figure 5I lanes 4 and 5; Figure 5J lanes 3 and 5). These 
results revealed a unique role of the central pair of TMs for LMP1-β-TrCP2 binding. 
-GFP lost this 
ability (Figure 5H). A mutant containing the TM-C-Flag also had the ability to bind β-TrCP2 
and even stronger than B95-8 LMP1 (data not shown). These results showed that the deletions 
of both N- and C-terminal cytoplasmic domains did not impair β-TrCP2 binding and thus 
highlighted a determinant role of the transmembrane domain for the interaction.  
In summary, these results show that LMP1 not only binds to β-TrCP2, but also to its homolog 
β-TrCP1. We showed that the interaction was mediated by β-TrCP2-WD40 domains and 
depended on the presence of LMP1 TMs 3 and 4. 
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Figure 5: The presence of TMs 3 and 4 is essential for β-TrCP2 binding. (A) Schematic representation of 
LMP1 and localization of the putative β-TrCP2 binding site. The DSG binding motif lies close to the TRAF 
binding site. Mutations in the CTAR and DSG sites are indicated. (B-F, H-J) Association of β-TrCP with LMP1. 
293T or HEK cells were transfected with the indicated β-TrCP and LMP1 constructs and lysed 38h later. 
Extracts were immunoprecipitated with S12 anti-LMP1 or HA antibodies bound to protein A Sepharose. LMP1 
immunoprecipitates (IP) and cells lysates were resolved by SDS-PAGE and analyzed by immunoblotting (IB) 
using the indicated antibodies. (B) HA-tagged β-TrCP2 binding to CTAR and DSG mutants in 293T cells with 
LMP1 immunoprecipitation. (C) HA-tagged β-TrCP2 binding to B95-8 LMP1 in HEK cells with LMP1 
immunoprecipitation. (D-E) HA-tagged β-TrCP2-WD domains binding to B95-8 LMP1 in HEK cells with 
LMP1 (D) and HA (E) immunoprecipitation. (F) Flag-tagged β-TrCP1 binding to B95-8 LMP1 in HEK cells 
with LMP1 immunoprecipitation. (G) Schematic representation of LMP1-GFP mutants. (H) HA-tagged WD-β-
TrCP2 binding to LMP1-GFP mutants in 293T cells with LMP1 immunoprecipitation. 8G3 epitope is located in 
the C-terminal region explaining the loss of detection of mutants lacking the C-terminal part. (I-J) HA-tagged  
β-TrCP2 binding to (I) TMs mutants with 4 TMs and (J) with 2 TMs in 293T cells with LMP1 
immunoprecipitation. pCR3.1: empty vector. 
 
4.2.6 LMP1 TMS AND INTRACELLULAR LOOPS L2 AND L4 CONTRIBUTED DIFFERENTIALLY TO NF-
ΚB ACTIVATION 
Two regions CTAR1 and CTAR2 within LMP1 C-terminal cytoplasmic domain have been 
shown to be critical for NF-κB activation (Figure 4A and 5A) [53]. As shown in the control 
experiment, mutation of the PxQxT motif of CTAR1 diminished the capability of LMP1 to 
activate NF-κB to 34% ± 12% of B95-8 LMP1 when measured by gene reporter assay (Figure 
6A and Table 1). Mutation of CTAR2 diminished the activation to 32% ± 7%, whereas the 
combined mutations of CTAR1 and CTAR2 abolished NF-κB activation completely. DSG 
mutants, containing mutations close the PxQxT motif of CTAR1, activated NF-κB at levels 
similar to the B95-8 LMP1 (Figure 6B and Table 1).  
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Multiple observations support a role for LMP1 TMs in signaling [50,57,93]. However, the 
lack of consistency among LMP1 mutants does not allow to draw conclusions about the 
relative importance of each pair of TMs. We first analyzed the signaling properties of LMP1 
TMs mutants with two pairs of TMs. As shown in Figure 6C, mutant TM3-4-5-6 had the 
lowest capability to activate NF-κB (45%) compared to the full length LMP1 (Table 1). 
Surprisingly, mutants TM1-2-3-4 and TM1-2+5-6(L2) activated NF-κB to the level of full-
length LMP1, despite the fact that they displayed impaired TRAF3 binding (Figure 4C). 
Mutant TM1-2+5-6(L4) has an intermediate level of activation of 75%. The further 
comparison of TM1-2+5-6(L2) and TM1-2+5-6(L4) revealed that the intracellular loops L2 
and L4 had a different impact on the signaling properties of the molecule. This observation 
suggests that L2 favored NF-κB activation or, alternatively, that L4 was associated with lower 
NF-κB activation levels. 
We then analyzed the ability of mutants carrying a single pair of TMs to activate NF-κB. The 
three mutants are able to activate the transcription factor, but at different levels (Figure 6D 
and Table 1). The 70% of NF-κB activation displayed by mutant TM1-2 confirmed the major 
importance of TMs 1 and 2 for signaling [94,143]. The lower NF-κB activation levels induced 
by TM3-4 and TM5-6 (55% and 27%, respectively) was consistent with a less efficient 
membrane insertion (Figure 2). It is interesting to note that despite the loss of TRAF3 binding 
and suboptimal membrane insertion, LMP1 mutants with a single pair of TMs mediate 
substantial NF-κB activation compared to CTAR1-/2-. 
Mutant TM1-2+5-6(L4) activated NF-κB less than TM1-2+5-6(L2). To better understand the 
function of the intracellular loop L4, we mutated residues that were conserved in B95-8 
LMP1 and Rhesus LMP1 (Figure 6E and 8A). Both LMP1 and RhLMP1 contain a di-leucine 
motif within L4. To assess the importance of this motif, we mutated L126 and L127 to 
alanines (mutant L4m2) (Figure 6F and Table 1). Similarly, we mutated to alanines two pairs 
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of residues located near or present in the loop 4: W123, Y125 (mutant L4m1) and G134, 
W138 (mutant L4m3).  
L4 mutants induced higher levels of NF-κB activation than B95-8 LMP1 (Figure 6G). L4m2, 
in which the di-leucine motif within L4 was replaced by two alanines, induced maximal  
NF-κB activation levels. The finding of several independent mutations near or in L4 with a 
positive impact on NF-κB signaling indicated a possible participation of the intracellular loop 
L4 in a negative regulation. 
In summary, these results highlighted the differential behavior of the TMs as well as the two 
loops L2 and L4. A possible negative regulation by L4 was shown by mutating into alanines 
residues that are conserved between human and rhesus LMP1. 
Table 1: 
NF-κB activation levels of LMP1 B95-8 prototype and CTAR, DSG, TMs and L4 mutants. 
LMP1 % SD p-value 
B95-8 100 -  
CTAR1- 34 12 **** 
CTAR2- 32 7 **** 
CTAR1-/2- 1 0 **** 
DSGm1 102 6 ns 
DSGm2 96 8 ns 
DSGm3 86 9 ns 
TM3-4-5-6 45 7 **** 
TM1-2+5-6(L2) 106 9 ns 
TM1-2+5-6(L4) 75 8 **** 
TM1-2-3-4 107 10 ns 
TM1-2 69 7 **** 
TM3-4 55 9 **** 
TM5-6 27 5 **** 
L4m1 156 18 **** 
L4m2 183 39 **** 
L4m3 157 23 **** 
 
NF-κB activities were measured 24 hours after transfection. Values are percentages ± SD of means of minimum 
9 independent transfections normalized to the activity of B95-8 LMP1 fixed at 100%. Statistical analysis was 
done using one-way ANOVA with Bonferroni posttest using GraphPad Prism. * P<0.05, ** P<0.01, *** 
P<0.001, **** P<0.0001 relatively to the NF-κB activation of B95-8 LMP1. RLU: relative light units. 
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Figure 6: NF-κB activation by LMP1 CTAR and TMs mutants. (A-D, G) 293T cells were transfected with a 
NF-κB Firefly luciferase reporter, a Renilla luciferase reporter and the indicated LMP1 constructs. Cells were 
lysed 24h later and assayed for light emission using a dual-luciferase assay. Results are reported as mean + SD 
of the ratio of Firefly versus Renilla luciferase activity from triplicate wells. Shown is a representative of three 
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separate experiments. RLU: relative light units. Extracts were assayed for LMP1 expression by Western blot 
(lower panel). The amount of LMP1 detected in each lane is representative of triplicate transfection in a single 
experiment. pCR3.1: empty vector. LMP1: B95-8 LMP1. NF-κB activation by (A) CTAR mutants, (B) DSG 
mutants, (C) TMs mutants with 4 TMs and (D) with 2 TMs, (G) L4 mutants. (E) Alignment of B95-8 and 
RhLMP1 in the region of the loop L4. (F) Schematic representation of L4 mutants. 
 
4.2.7 LMP1 INHIBITS MAVS-MEDIATED INTERFERONΒ ACTIVATION 
As mentioned before, TRAF3 was the first LMP1 interacting partner described [55]. LMP1 
recruits endogenous cytoplasmic TRAF3 to lipid rafts [106] and TRAF3 sequestration by 
LMP1 is the key event leading to the activation of the alternative NF-κB pathway 
[151,152,153]. Recent work showed that TRAF3 is also an essential activator of type I 
interferon production and thus is a critical link between NF-κB and IRF3 signaling pathways 
[154,155,156,157].  
To investigate the impact of LMP1 on the IFNβ signaling pathway and test a possible 
correlation with LMP1’s ability to bind TRAF3 or activate NF-κB we used reporter genes for 
NF-κB, ISRE and IFNβ-promoter (described in Materials and Methods). We observed that 
LMP1 B95-8 was able to activate the NF-κB reporter plasmid but not the ISRE and IFNβ-
promoter reporter plasmids (Figure 7A). As previously observed in Figure 6A, the CTAR 
mutants had decreased abilities to activate NF-κB. None of the LMP1 proteins had the ability 
to activate ISRE and IFNβ-promoter reporter genes. In contrast, strong activations of ISRE 
and IFNβ-promoter reporter genes were measured upon overexpression of MAVS. 
Transcriptional activation of the IFNβ-promoter requires assembly of a multiprotein complex, 
which consists of activating transcription factor (ATF)2, c-Jun, IRF3 and NF-κB [36,158]. 
Our experiments showed that despite being a strong activator of c-Jun/AP-1 [159] and NF-κB, 
LMP1 did not activate the IFNβ-promoter. 
A physical interaction between TRAF3 and MAVS has been recently demonstrated [157]. 
According to a model in which TRAF3 positively regulates MAVS the sequestration of 
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TRAF3 by LMP1 should inhibit MAVS-mediated ISRE activation. We tested this hypothesis 
by overexpressing RIG-I, MAVS, TBK-1 and IKKε, which all activated the ISRE reporter 
plasmid in presence of a 1:1 ratio of LMP1 or the control protein EGFP (Figure 7B). Whereas 
ISRE activation by TBK-1 and IKKε was not impaired by the co-expression of LMP1 B95-8, 
its activation by RIG-I and MAVS was specifically affected (Figure 7B). This result indicated 
that LMP1 blocked MAVS-mediated ISRE activation upstream of TBK-1 and IKKε.  
We further measured the influence of the expression of LMP1 mutants on MAVS-mediated 
activation of ISRE and IFNβ-promoter reporter genes. As shown previously, CTAR1- and 
CTAR1-/2- did not bind TRAF3 (Figure 4B). Although CTAR1- and CTAR1-/2- were not as 
effective as B95-8 LMP1 in blocking MAVS-mediated ISRE and IFNβ-promoter activation, 
both mutants clearly displayed inhibitory activities. The data showed that TRAF3 binding 
leads to a mild inhibition and indicated that TRAF3 was not the unique mechanism by which 
LMP1 blocked MAVS-mediated ISRE activation. Moreover, the lack of inhibition by 
CTAR2- suggested that complex regulatory processes may be involved. 
Inhibition of the IRF3 signaling pathway is a novel function of LMP1 that has not been 
described before. We further tested whether it required the integrity of the transmembrane 
region.  Most interestingly, TM1-2+5-6(L4) totally lost the ability to inhibit ISRE and IFNβ-
promoter reporter genes, whereas TM3-4-5-6, TM1-2+5-6(L2) and TM1-2-3-4 kept residual 
inhibitory activities (Figure 7D). These results again highlighted the differential properties of 
the two intracellular loops L2 and L4. LMP1 mutants with a single pair of TMs did not inhibit 
ISRE and IFNβ-promoter reporter genes effectively (Figure 7E), the highest inhibitory effect 
was displayed by TM5-6 with about a 10% of inhibition level. 
In summary, we described a novel property of the LMP1 oncogene, the inhibition of MAVS-
mediated ISRE and IFNβ-promoter activation. We showed that the binding of TRAF3 by 
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LMP1 played a minor role in this process. Finally, the integrity of the transmembrane domain 
of LMP1 was critical to this inhibitory activity.  
 
Figure 7: LMP1 inhibited MAVS-mediated activation of IFNβ pathway. (A) Activation of NF-κB, ISRE and 
IFNβ-promoter reporter plasmids by different LMP1 and MAVS. HEK cells were co-transfected with 50 ng of 
one reporter plasmid and 50 ng of expression vectors encoding for LMP1 or MAVS. (B-E) HEK cells were  
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co-transfected with 50 ng of either ISRE-luc or IFNβ-luc and 25 ng of expression vector for MAVS and 25 ng of 
expression vector for LMP1. Transfection with the empty vector pCR3.1 was used as basal level. Transfection 
with EGFP was used as control for the effect of the expression of unrelated protein. (B) Activation of ISRE 
reporter gene by different activators of the pathway and effect of LMP1 B95-8. EGFP was used as negative 
control. (C) Inhibition of MAVS-mediated ISRE and IFNβ pathways by LMP1. (D-E) Inhibition of MAVS-
mediated activation of ISRE and IFNβ reporter genes by TMs mutants (D) with four TMs and (E) with two TMs.  
 
4.2.8 RHLMP1 AND EBV LMP1 SHARE SIMILAR FUNCTIONAL PROPERTIES. 
EBV shares many molecular and biologic features with simian lymphocriptoviruses naturally 
infecting primates [160,161]. Franken and co-workers isolated and characterized the LMP1 
homolog RhLMP1 from EBV-related rhesus lymphocryptovirus (cercopithicine Herpesvirus 
15) [162]. LMP1 and RhLMP1 shared an overall homology of 27.2% (Figure 8A). 
Interestingly, a good conservation was observed within the six TMs with 54.9% homology 
among residues 25 to 186. In contrast, the two C-terminal domains were strikingly divergent, 
except for the last 22 amino acids comprising CTAR2. 
RhLMP1 C-terminal domain contains five putative TRAF binding sites PxQxT/S but no 
putative β-TrCP binding motif DSG. We extended previous observations [162] by showing 
that RhLMP1 bound endogenous TRAF3 (Figure 8B) and activated NF-κB very effectively as 
assessed by gene reporter assay (Figure 8C). Moreover, we demonstrated by co-IP 
experiments that RhLMP1 was able to interact with β-TrCP2 and the WD40 domains of  
β-TrCP2 (Figure 8D). RhLMP1 also shared with LMP1 the ability to inhibit MAVS-mediated 
ISRE and IFNβ-promoter activation (Figure 8E). The lower efficacy of RhLMP1 ompared to 
B95-8 is likely due to its lower expression level. Our observations indicated that the different 
features were common to human LMP1 and RhLMP1, despite major sequence divergences in 
the C-terminal domains. 
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 Figure 8: Rhesus LMP1 shared common features with human LMP1. (A) Alignment of B95-8 LMP1 and 
RhLMP1. Alignment and measure of homology was performed using Geneious software. The 6 TMs are 
highlighted by black lines. The strength of the homology was depicted with a black-white gradation. (B-C) 
Association of endogenous TRAF3 (B) or HA-tagged β-TrCP2 (C) with B95-8 LMP1 and RhLMP1. 293T cells 
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were transfected with Flag-tagged LMP1 constructs and (C) HA-tagged β-TrCP2, lysed 38h later. Extracts were 
immunoprecipitated with anti-FlagM2 beads. LMP1 immunoprecipitates (IP) and cells lysates were resolved by 
SDS-PAGE and analyzed by immunoblotting (IB) using the indicated antibodies. (D) NF-κB activation by  
B95-8 LMP1 and RhLMP1. HEK cells were transfected with 50 ng of LMP1 vector and 50 ng of NF-κB reporter 
plasmid. Empty vector was used as control. NF-κB activity was measured 24h after transfection using luciferase 
assay (Promega). Shown are representative of three independent experiments with similar results. Data are given 
as mean ± SD of triplicates. (E) Inhibition of MAVS-mediated activation of ISRE and IFNβ reporter genes by 
LMP1 and RhLMP1. HEK cells were co-transfected with 50 ng of either ISRE-luc or IFNβ-luc and 25 ng of 
expression vector for MAVS and 25 ng of expression vector for LMP1 or RhLMP1. Transfection with the empty 
vector pCR3.1 was used as basal level. Transfection with EGFP was used as control for the effect of the 
expression of unrelated protein. 
 
4.2.9 B95-8 LMP1 AND VARIANT A2 SHARED FUNCTIONAL PROPERTIES 
We have seen in the Chapter 1 the great diversity of natural LMP1 variants and their ability to 
display different levels of NF-κB activation. We have taken B95-8 and A2 LMP1 as examples 
to show the good conservation among variants of LMP1 functional properties. 
We already knew that A2 displayed increased levels of NF-κB activation (Figure 9A and 
Chapter 1). Similarly to B95-8 LMP1, variant A2 interacted with TRAF3 (Figure 9 B) and  
β-TrCP2-WD40 domains (Figure 9C). As B95-8 LMP1, A2 did not activate ISRE and  
IFNβ-promoter by itself (Figure 9A) and inhibited MAVS-mediated ISRE and IFNβ-promoter 
activation (Figure 9D). 
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Figure 9: B95-8 LMP1 and variant A2 shared functional properties. (A) Activation of NF-κB, ISRE and 
IFNβ-promoter reporter plasmids by LMP1 and MAVS. HEK cells were co-transfected with 50 ng of one 
reporter plasmid and 50 ng of expression vectors encoding for LMP1 or MAVS. (B-C) Association of TRAF3 
and β-TrCP2 with A2 LMP1. Cells were transfected with the indicated constructs, lysed 38h later and extracts 
were immunoprecipitated with S12 anti-LMP1 antibodies bound to protein A Sepharose. LMP1 
immunoprecipitates (IP) and cells lysates were resolves by SDS-PAGE and analyzed by immunoblotting (IB) 
using the indicated antibodies. (B) HEK cells were transfected with LMP1 constructs. Binding of the 
endogenous TRAF3 with LMP1 was analyzed. (C) 293T cells were co-transfected with HA-tagged β-TrCP2-
WD domains and LMP1 constructs. pCR3.1: empty vector. (D) Inhibition of MAVS-mediated ISRE and IFNβ 
pathways. HEK cells were co-transfected with 50 ng of either ISRE-luc or IFNβ-luc and 25 ng of expression 
vector for MAVS and 25 ng of expression vector for LMP1. Transfection with the empty vector pCR3.1 was 
used as basal level. Transfection with EGFP was used as control for the effect of the expression of unrelated 
protein.  
 
4.2.10 ANALYSIS OF NATURALLY OCCURRING POLYMORPHISMS IN TMS 
In view of the importance of TMs for LMP1’s functions, genetic variations in the 
transmembrane region of the protein merit significant attention. 
We reported all polymorphisms identified between aa 25 to 186 in LMP1 variants 
characterized in Chapter 1 (Figure 10, Appendix 1 for full length sequences). 
When compared to the B95-8 LMP1 prototype sequence, the  number of amino acid changes 
in this region ranged from two (variant 7835) to 15 (variant A2). It is to note that these 
numbers included two polymorphisms I85L and F106Y that were identified in all LMP1 
isolates except B95-8. 
Variations were identified in all six transmembrane segments. However, in most cases the 
amino acid changes were highly conservative. Most interestingly, we did not identify any 
polymorphism in the intracellular loop L2. 
The phylogenetic groups described in the Figure 3 of Chapter 1 could be defined from the 
polymorphisms in the transmembrane region. In particular, variants from group 1 and 2 each 
display a very distinctive set of linked polymorphisms and few rarer variants. 
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Finally, some key residues identified in B95-8 LMP1 were not conserved in all variants. 
These include leucine 29 and leucine 36 in the Leucin heptad [143], cystein 78, which was 
shown to be palmitoylated [163], and methionine 129, which was described as the initiation 
methionine of lytic LMP1 [48,164,165] . 
 
 
 Figure 10: Schematic representation of LMP1 protein and table of polymorphisms present in the TMs 
and loops of the variants analyzed in Chapter 1. The sequence of reference is the B95-8 LMP1 prototype. The 
different variants were listed according to the phylogenetic tree constructed in Chapter 1 Figure 3. Only the 
positions changing were described. For the full sequences alignment see Appendix 1. 
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4.3 CHAPTER 2 – MATERIALS AND METHODS 
4.3.1 PLASMIDS 
The expression vectors for EBV B95-8 strain full length LMP1 was constructed by cloning 
the LMP1 gene from the lymphoblastoid cell line B95-8 [106] into pCR3.1 (Invitrogen). The 
following deletions were introduced by PCR: TMs mutants: TM3-4-5-6 (deletion of amino 
acids 25 to 76), TM1-2+5-6 (L2) (deletion of amino acids 77 to 138), TM1-2+5-6 (L4) 
(deletion of amino acids 73 to 125), TM1-2-3-4 (deletion of amino acids 126 to 186), TM1-2 
(deletion of amino acids 73 to 186), TM3-4 (deletion of amino acids 25 to 76 and 126 to 186), 
TM5-6 (deletion of amino acids 25 to 138). GFP mutants: LMP1-GFP contains full-length 
LMP1 fused in C-terminal to GFP and Flag tag. N-TM-GFP contains the N-terminal domain 
and the six TMs fused to GFP and Flag tag. TM-GFP contains the six TMs fused to GFP and 
Flag tag. C-GFP contains the whole C-terminal domain fused to GFP and Flag tag. C232
82
-GFP 
contains the 154 last amino acids of the C-terminal part of LMP1 fused to GFP and Flag tag. 
Flag-tagged LMP1 was constructed by fusing the C-terminal part of LMP1 to Flag tag. Point 
mutations were introduced by PCR using the full length LMP1 as template. CTAR mutants: 
CTAR1- has the PxQxT TRAF binding motif mutated into alanines, CTAR2- contains the 
mutation L382P and CTAR1-/2- has both CTAR sites mutated. DSG mutants: DSGm1 
contains mutations of the canonical and cryptic recognition sites described in [ ]. DSGm2 
has the two serines of the DSGxxS motif mutated. DSGm3 has, besides the mutations of the 
two serines, changes in the acidic residues present in the DSG region. All LMP1 constructs 
were cloned into pCR3.1 and verified by sequencing.  
The expression vector for RhLMP1 was a gift of F. Wang (Boston, USA). It encodes an  
N-terminally Flag-tagged LMP1 homologue from simian EBV infecting rhesus monkeys 
(cercopithicine herpes virus 15) [162]. 
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The expression vectors for Flag-tagged β-TrCP1 [166] and HA-tagged β-TrCP2 [167] were 
the gift of Y. Ben Neriah (Jerusalem, Israel) and S. Fuchs (Philadelphia, USA), respectively. 
The construct encoding the WD40 domain of β-TrCP2 (amino acids 215 to 542) was built by 
PCR.  
The expression vector for EGFP was given by S. Kunz (Lausanne, Switzerland). 
The reporter construct κB-conA-luc, provided by F. Grässer (Homburg, Germany), comprises 
the Firefly luciferase gene under the control of a conalbumine promoter with three integrated 
κB elements derived from the immunoglobuline κ chain enhancer (Figure 11).  
pISRE-luc reporter vector (Stratagene), provided by M. Thome (Lausanne, Switzerland), 
expresses the Firefly luciferase gene under the control of a synthetic promoter containing five 
enhancer elements (TAGTTTCACTTTCCC)5 
IFNβ-luc reporter vector, provided by M. Thome, expresses the Firefly luciferase gene under 
the control of the human IFNβ promoter that harbors responsive elements for AP1, (ISRE)
of the transcription recognition sequences for 
the interferon-stimulated response element (ISRE). pISRE-luc is stimulated by IFNα and 
IFNβ and regulated by IRF3. 
2
168
 
and NF-κB [ ].  
The Renilla luciferase construct pRL-RSV, provided by E. Buetti (Lausanne, Switzerland), 
was constructed by inserting the BglII-HindIII fragment containing the RSV LTR from 
pRc/RSV (Invitrogen) into the plasmid pRL-null (Promega). 
CHAPTER 2 - LMP1: IMPORTANCE OF TRANSMEMBRANE SEGMENTS 79 
 
  
Figure 11: Schematic representation of the promoters of Firefly luciferase gene reporters. For the 
description see the Plasmids section of Materials and Methods. 
 
4.3.2 ANTIBODIES 
4.3.2.1 Primary antibodies 
The following antibodies rat monoclonal against HA tag – 1:3,000 - 1:4,000 (Roche Applied 
Science), mouse IgG1 monoclonal Flag tag – 1:10,000 (M2, Sigma), mouse IgG1 monoclonal 
transferrin receptor – 1:3,000 (Zymed), mouse IgG2a monoclonal caspase-3 – 1:3,000 (Signal 
transduction), mouse antibody against tubulin – 1:10,000 (Sigma), as well as rabbit polyclonal 
antibodies against TRAF3 – 1:1,000 (Santa Cruz) were purchased. S12 mouse IgG2a 
monoclonal antibody – 1:24,000 - 1:48,000 [45,169] and 8G3 rat monoclonal antibody – 
1:500 - 1:1,000 [108] against LMP1 were provided by F. Meggetto (Toulouse, France) and  F. 
Grässer, (Hombourg, Germany), respectively. Both anti-LMP1 antibodies recognize epitopes 
located in the C-terminal domain of the protein.  
4.3.2.2 Secondary antibodies 
Secondary antibodies used after primary incubation were all purchased: polyclonal rabbit 
anti-mouse HRP and polyclonal rabbit anti-rat HRP – 1:3,000 - 1:5,000 (Dako Cytomation, 
3x κB responsive elements
ConA-luc
5x ISRE
ISRE-luc
AP1 (ISRE)2 NF-κB
IFNβ-luc
IFNβ-promoter
A
B
C
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Glostrup, Denmark), anti-rabbit HRP – 1:3,000 (Santa Cruz), goat anti-mouse IgG2a HRP – 
1:10,000 and IgG1 HRP – 1:6,000 (SouthernBiothech, Birmingham, UK). 
 
4.3.3 CELL CULTURE  
Human embryonic kidney 293 T (293T) cells (ATCC CRL-1126)  and Human embryonic 
kidney 293 (HEK) cells (ATCC CRL-1573) [107] were cultured in Dulbecco’s modified 
Eagle medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum, penicillin 
and streptomycin at 37o
 
C with 5% CO2.  
4.3.4 SUBCELLULAR FRACTIONATION 
293T cells from 100-mm plates were washed once in cold PBS and resuspended in 1 ml 
homogenization buffer (20 mM Tris HCl pH7.4, 10 mM EDTA, 5 mM EGTA) supplemented 
with inhibitors of proteases (minicomplete, Roche Applied Biosytems). Cells were broken 
with 100 strokes of a tight-fitting pestle in a dounce homogenizer. The nuclei and unbroken 
cells were removed by a low speed centrifugation (500 xg for 5 min at 4°C). The 
homogenates were centrifuged at 100,000 xg for 1 h at 4°C. The high speed supernatant 
(soluble fraction) was removed and pellets including membranes were resuspended in an 
equal volume of homogenization buffer containing 1 % Triton X-100. Both fractions were 
analyzed by SDS-PAGE. 
 
4.3.5 CELL LYSIS, IMMUNOPRECIPITATION AND IMMUNOBLOTTING 
293T cells were transfected in 100-mm plates with 2 μg of the expression plasmids using 
Fugene 6 (Roche Applied Science). All transfections were equalized using the empty vector 
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pCR3.1. Thirty-eight hours post-transfection cells were lysed in RIPA buffer (150 mM NaCl, 
20 mM Tris-HCl pH 8, 0.5% sodium deoxycholate, 1% Triton X-100, 0.1% SDS) 
supplemented with inhibitors of proteases (minicomplete, Roche Applied Science) and 
inhibitors of phosphatases (20 mM NaF, 25 mM glycerophosphate, 1 mM orthovanadate). 
Lysates were cleared by centrifugation at 16,000 xg for 10 min at 4°C. Fifty μl of lysate were 
saved and used to detect the level of each protein. Proteins were immunoprecipitated with 
either M2-agarose beads or S12-bound protein-A Sepharose for 2 h at 4°C. Precipitates were 
washed three times with RIPA buffer and twice with phosphate buffered saline. Samples were 
boiled for 4 min in 50 μl of 2x sample buffer (62 mM Tris-HCl pH 6.8, 20% glycerol,  
2% SDS, 100 mM DTT). Samples were separated through SDS-polyacrylamide gel 
electrophoresis, transferred to nitrocellulose, probed with the appropriate antibodies and 
revealed by chemiluminescence.  
 
4.3.6 REPORTER GENE ASSAYS 
293T cells were transfected in 24-well plates with 50 ng of the NF-κB Firefly reporter 
construct κB-conA-luc, 2.5 ng of the Renilla reporter construct pRL-RSV and 50 ng of LMP1 
expression vectors using Fugene 6 (Roche Applied Science). Twenty-four hours after 
transfection, cells were lysed in Passive lysis buffer (Promega) and assayed for light emission 
on a Bertold Lumat LB 9507 luminometer using the Dual-Luciferase Reporter Assay System 
(Promega, Amriswil, Switzerland). All transfection efficiencies were normalized to the levels 
of Renilla luciferase. Final quantifications were performed on three separate experiments 
executed in triplicates.  
HEK cells were transfected in 24-well plates with the indicated amount of the different 
reporter constructs κB-conA-luc, ISRE-luc or IFNβ -luc and with the indicated amount of 
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expression vectors encoding for LMP1 constructs, pCR3.1 empty vector, EGFP or MAVS 
using FuGENE6. Twenty-four hours after transfection, cells were lysed in Cell Culture Lysis 
Reagent (Promega) and assayed for light emission in a Bertold microplate luminometer 
Tristar LB 941 using Luciferase Assay System (Promega).  
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4.4 CHAPTER 2 – DISCUSSION 
In the present study we found that diverse biological properties of LMP1 crucially depend on 
its six transmembrane-spanning segments. TMs ensured membrane insertion, self-
aggregation, contributed to the recruitment of cellular proteins and modulated signaling. In 
particular we showed that the three pairs of TMs and the two intracellular loops that link them 
are not functionally equivalent and interchangeable.  
Previous observations supported a key role for LMP1’s TMs in signaling: a derivative of EBV 
with a LMP1 gene lacking the entire transmembrane region transformed B cells with less than 
1% of the efficiency of the full length form [96] and studies using chimeric proteins between 
LMP1 and CD40 demonstrated that LMP1 signals in a ligand-independent fashion due to its 
six TMs (24, 28, 32, 39). However the relative importance of TMs has not been evaluated 
before. To address this question we generated LMP1 mutants with deletions of either one or 
two pairs of TMs. Importantly, all constructs had identical N- and C-terminus and were 
equally well expressed in cells upon transfection. Moreover, all TMs mutants including 
mutants with a single pair of TMs induced substantial NF-κB activation compared to  
CTAR1-/2-, demonstrating that C-terminus were accessible to cytoplasmic factors and thus 
oriented correctly. 
LMP1 TMs are particularly rich in leucine and isoleucine residues. Previous studies focusing 
on TM 1 demonstrated by alanine mutagenesis that the leucin heptad and residues FWLY 
contributed to intermolecular interactions and signaling [93,94,143]. We performed cellular 
fractionation to assess the membrane association of the LMP1 mutants. We found that TM3-4 
and TM5-6 drove a less efficient membrane insertion compared to TM1-2. Concordantly, 
TM3-4 or TM5-6 activated NF-κB to lower levels compared to TM1-2 in a gene reporter 
assay. NF-κB activation levels were correlated with the Grand average of hydropathicity 
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(GRAVY) index of the TMs: the combined GRAVY of TMs1-2 is the highest, that of TMs  
3-4 intermediate, and that of TMs 5-6 the lowest.   
We evaluated self-aggregation of LMP1 mutants with a single pair of TMs in co-
immunoprecipitation experiments and found that all three pairs of TMs participated in self-
association and association with neighboring LMP1 molecules. However in the absence of a 
crystal structure and the lack of homology to proteins with known crystallographic data, it is 
impossible to draw conclusions about the exact spatial organization of LMP1 TMs.  
Co-immunoprecipitation analysis indicated that the three pairs of TMs engaged 
intramolecular and intermolecular interactions and that the central pair of TMs seemed to play 
a key part in LMP1 aggregation as TM3-4 led to the strongest associations. 
We used LMP1 mutants to assess the binding to endogenous TRAF3 and found that the 
deletion of a single pair of TMs strongly impaired TRAF3 binding. Despite impaired TRAF3 
binding, mutants with two pairs of TMs induced higher activation levels than CTAR1-. 
Surprisingly TM1-2+5-6(L2) and TM1-2-3-4 even induced levels similar to full length B95-8 
LMP1. These results, together with the differential activation by TM1-2+5-6(L2) and TM1-
2+5-6(L4), are compatible with a negative regulation of NF-κB signaling in the 
transmembrane region. The finding that mutations within the intracellular loop L4 led to 
enhanced NF-κB activation compared to B95-8 LMP1 further support this hypothesis.  
Little is known about the interaction between LMP1 and β-TrCP. The F-box protein β-TrCP 
serves as the substrate recognition subunit in the SCFβ-TrCP E3 ubiquitin ligase complex that 
plays a pivotal role in cell cycle progression, cell survival and signaling. The majority of  
β-TrCP substrates contain a canonical DSGxxS motif in which the phosphorylation of the two 
serine residues is required to allow recognition. Although LMP1 contains a canonical 
DSGxxS motif in the C-terminus, this motif was dispensable for β-TrCP2 binding. We found 
that LMP1 with mutations S211A /S215A either alone, or in combination with the mutation 
CHAPTER 2 - LMP1: IMPORTANCE OF TRANSMEMBRANE SEGMENTS 85 
 
of the adjacent residues D210N/E214Q/D216N bound β-TrCP2 as efficiently as B95-8 LMP1. 
Moreover, RhLMP1 bound β-TrCP2 despite the absence of a DSGxxS motif in its sequence. 
Instead we found that the interaction was driven by LMP1 TMs and did not require the F-box 
domain of β-TrCP2. The biological relevance of this association remains largely unknown. 
Since IκB is a target of β-TrCP, the interaction may modulate LMP1-mediated NF-κB 
activation. Initial studies showed that overexpression of a dominant negative β-TrCP2 did not 
change LMP1’s half-life [82], suggesting that the E3 ubiquitin ligase activity of SCFβ-TrCP
170
 
does not target LMP1 for degradation. Most interestingly, alternative binding sites were 
described for hnRNP-U [ ], growth hormone receptor [171] and USP47 [172], indicating 
that other modes of interaction with β-TrCP2 exist. It is to note that these interactions were 
similarly not linked to the degradation of the target protein. 
Evidences of a direct interaction between TRAF3 and MAVS [173] suggested to us that 
TRAF3 sequestration by LMP1 may impair MAVS function. To test this hypothesis we took 
advantage of the observation that MAVS, when overexpressed in cells, induced efficiently 
ISRE and IFNβ-promoter reporter genes [174]. Using this assay we discovered that LMP1 
was a strong inhibitor of MAVS-mediated ISRE and IFNβ-promoter activation. The 
biological advantage of such an inhibition may be multiple for EBV in the context of viral 
persistence in memory B-cells and tumors. In cells latently infected with EBV, EBER1 and 
EBER2 are the most abundant viral transcripts and EBERs are considered reliable markers for 
the detection of EBV in tumors [175]. EBER1 and EBER 2, which are small uncapped, 
polyA-, non-coding, non-translated RNA form extensive secondary structures that could 
induce the expression of type I INFs through direct activation of RIG-I in Burkitt’s lymphoma 
derived cells [175,176]. Interestingly, the transcriptome analysis of EBV-transformed 
lymphoblastoid cell lines which express LMP1 revealed a two- to four-fold suppression of 
INFα and IFNβ gene expression [177]. 
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We found that TRAF3 binding to LMP1 only modestly contributed to the inhibition of a 
MAVS-mediated ISRE and IFNβ-promoter activation. Instead, LMP1 TMs and intracellular 
loop L2 played a key role. Our results also indicated that LMP1 targets either MAVS or a 
positive regulator of MAVS and not the downstream kinases TBK-1 and IKKε. Interestingly, 
LMP1 did not induce MAVS degradation (data not shown), suggesting that molecular 
mechanisms involved are different from those described for hepatitis C virus [168]. LMP1 
may block MAVS-induced signaling cascade at the interface between the endoplasmic 
reticulum and the mitochondria. LMP1 was shown to signal principally from intracellular 
compartments [178] and to interact through the transmembrane domain with prenylated Rab 
acceptor 1 (PRA1, also designated as PRA1 domain family member 2, PRAF2) [179], a 
multispan protein implicated in vesicular traffic and lipid metabolism. It will be of greatest 
interest to test whether LMP1 interacts through the transmembrane region with the MAVS 
regulator stimulator of interferon genes (STING, also known as MITA, ERIS, MPYS), a 
multispan protein localized to the endoplasmic reticulum membrane.  
In conclusion, the present study showed that TMs were implicated in broader biological 
functions than previously reported by providing a platform where association with the 
membrane, intramolecular and intermolecular interactions and binding to cellular proteins 
occurred. Therefore transmembrane segments could be considered as essential modulators of 
LMP1’s activities.  
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In Chapter 1, we determined which polymorphisms were involved in the increased NF-κB 
activation phenotype displayed by some LMP1 variants. Surprisingly, we found single 
polymorphisms as responsible for the major difference in NF-κB activation levels. F106Y and 
F144I were defined as important determinants for higher NF-κB activation levels; whereas 
I124V was described for the first time in this study. 
F106Y is present in all variants we cloned and moreover at a high frequency in LMP1 
described in the literature. It is present in CAO LMP1 [71,72], AG876 LMP1 [18] and in 
different LMP1 subgroups: A, B, C and D described by Fielding et al. [111] and Ch1, Ch2, 
AL and NC described by Edwards et al. [109]. Our study showed that the effect of 
polymorphism F106Y is modulated according to the variants. In the majority of the variants 
F106Y is not main feature associated with enhanced NF-κB activation, as shown with A2 
variant or in CAO [50]; whereas in variants 7795, 7815, 7918, 7948 and 7821 it is the major 
determinant leading to high NF-κB activation levels. Further work will be needed to better 
understand how other polymorphisms modulate the effect of F106Y. 
F144I has a more restricted distribution. It is present in CAO LMP1, AG876 LMP1 and in 
subgroups C [111], Ch2 and AL [109]. Moreover F144I is present at a high frequency in 
published sequences of LMP1 from EBV-associated NPC: 5/5 variants isolated from 
Vietnamese patients [180], 21/21 variants isolated from patients in Southern China [181], 5/5 
variants isolated from patients in Hong Kong [182]. These observations suggest either a more 
aggressive potential of these LMP1 strains or as markers of geographical origin of the strain.  
 
With the clinical pilot study on the potential association of LMP1 polymorphisms with HL, 
we demonstrated the feasibility and interest of such a study even if the statistical power was 
too low to draw definitive conclusions on the lack of association found. The further step of 
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this work would be the extension to a larger cohort and inclusion of a higher number of HL 
cases to increase the statistical power of the study in order to have more reliable results 
(Appendix 2).  
 
In Chapter 2, a more biochemical aspect of the LMP1 field was approached. In this study, we 
improved the knowledge about the relative contribution of each pair of LMP1 TMs regarding 
membrane association, self-aggregation, binding to LMP1 cellular partners TRAF3 and β-
TrCP, and NF-κB activation. We described an unknown function of LMP1, which consists in 
the repression of MAVS-mediated ISRE and IFNβ-promoter reporter genes. It would be 
relevant to further investigate the molecular mechanisms involved in this new function. 
Furthermore, since we cloned from SHCS samples a wide collection of LMP1 variants, it 
would be of great interest to test the different features with some variants representative of the 
different phylogenetic groups. 
 
Overall we have shown in this work the importance of the transmembrane domain of LMP1. 
All critical polymorphisms reside in LMP1 TMs 4 and 5. Finally, we have demonstrated the 
importance of the TMs for the regulation of LMP1 signaling. 
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7.1 AMINO ACID SEQUENCE OF LMP1 VARIANTS 
 
 
 
 
Schematic representation of LMP1 gene (upper) with the position of the two introns and protein (lower) with the six transmembrane domains 
represented by grey boxes, the region of the direct repeats and the position of the two deletions.  
 
 
Alignment of LMP1 variants used in the study and specific GenBank accession number (BankIt1498710) for each new LMP1 sequence: 
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7769    .............Q........S.....T......................A.......................QGPDNTDDNGP-----.G.......  
7926    ........H..A................T......................A.............G.........QGPDNTDDNGP-----.G.......  
7795    ...........S................T......................A.......................QGPDNTDDNGP-----.G.......  
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7843    -----------------------------------......N............D...........R...S.......----------..........T.  
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7821    ...................* 7821 JQ240467 
7893    ...................* 7893 JQ240468 
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7.2 EXERCISE OF FICTIVE PROTOCOL  
This fictive protocol was written in the context of a certificate in clinical research done the 
last year of my PhD studies. This protocol will be a possible continuation of the clinical study 
developed in the Chapter 1. Since our study has a low power due to few patients HIV-HL in 
the SHCS, increasing the sample size will increase the power of the study and thus confirm or 
infirm the results obtained in the pilot study. 
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